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1 Summary 
Influenza A/H5N1 viruses caused several panzootic outbreaks in the past. These 
viruses of avian origin have acquired a zoonotic potential by gene reassortment and 
mutations and can cross species barriers including humans. There is an urgent need of 
reliable broad spectrum H5N1 diagnostics. Therefore, the aim of this work is to identify 
H5 specific antibodies that can be applied in a subtype specific diagnostic system for 
the detection and discrimination of different influenza viruses. 
In this work two single chain (sc)Fv antibody gene phage libraries were generated 
using chickens vaccinated and challenged with avian H5N1 influenza viruses from 
phylogenetically distant clades. For selection of antibodies two additional recombinant 
H5 antigens of human and avian origin were applied. Twelve unique anti-H5 scFvs 
were isolated from generated anti-H5 chicken immune phage libraries and were 
subsequently re-cloned into the bivalent IgG-like scFv-Fc antibody format for 
expression in mammalian cells. All of them showed binding to H5 hemagglutinin 
proteins in immunoblot assays and in ELISAs. No cross-reactivity with unrelated 
proteins was observed. The majority of selected binders detected a large variety of H5 
viruses in immunoperoxidase monolayer assays (IPMA) and showed no cross-reactivity 
with other influenza viruses of closely related HA-subtypes H1, H2, H6 and H7. One 
antibody clone (JM7_8) showed very broad binding specificity for H5 ranging from 
LPAIV North American strains to HPAIV viruses of clade 2.2.1. Furthermore, 
neutralizing activity of those two antibody clones was demonstrated. Epitope mapping 
on peptide spot membranes revealed a six amino acid short epitope which is highly 
conserved among H5 influenza viruses. With a combination of scFv-Fc antibodies 
different recombinant H5 proteins as well as a selection of viruses of the H5 subtype 
were detected in sandwich ELISA and membrane based immunodot blot assay, 
demonstrating the proof of principle of a rapid diagnostic assay. Antibodies specifically 
stained influenza viruses of a purified avian low pathogenic H5 strain in transmission 
and scanning electron microscopy.  
Thus, a successful immunization and selection strategy comprising four different H5 
sources leading to the isolation of several H5 specific antibodies and elucidating a 
highly conserved linear epitope specific for H5 influenza viruses has been 
demonstrated. Isolated antibodies and the elucidated highly conserved linear epitope in 
the HA1 domain of the protein can be used in different applications e.g. influenza 
diagnostics, therapy and vaccination. 
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2 Zusammenfassung 
 
Influenza A/H5N1-Viren haben in der Vergangenheit verschiedene Pandemien 
verursacht. Diese humanpathogenen Viren aviären Ursprungs haben durch 
Genaustäusche und Mutationen die Fähigkeit erworben, Artbarrieren zu überwinden. 
Für H5N1 besteht ein dringender Bedarf an Breitspektrum-Diagnostika. Derzeit ist das 
hochkonservierte Nukleoprotein das Zielprotein mit der weitesten Verbreitung bei 
Antikörper-basierten Diagnostika für Influenzaviren. Ziel dieser Arbeit war es daher, 
H5-spezifische Antikörper zu identifizieren, die in einem subtypspezfischen System 
zum Nachweis und zur Unterscheidung von Influenzaviren anderen Subtypes 
eingesetzt werden können. 
Nach Vakzinierung von Hühnern mit aviären H5N1-Viren aus phylogenetisch 
entfernten „Clades― wurden in dieser Arbeit zwei single-chain (scFv) Phage-Display 
Antikörperbibliotheken hergestellt. Zur Selektion der Antikörperfragmente wurden zwei 
zusätzliche rekombinante H5-Antigene verwendet. Aus den generierten anti-H5-
Antikörperimmunbibliothekenaus immunisierten Hühnern wurden 12 unterschiedliche 
H5 spezifisch scFv-Fragmente isoliert und nachfolgend zur Säugerzell-Expression in 
das bivalente IgG-ähnliche scFv-Fc-Format umkloniert. Alle scFv-Fc-Antikörper binden 
beide H5-Antigene in Immunoblot- und in ELISA-Experimenten. Kreuzreaktivität mit 
weiteren Proteinen zeigte sich nicht.  
Die Mehrzeit der selektierten Binder erkannte eine große Bandbreite an H5-Viren in 
Immunoperoxidase Monolayer Assays (IPMA) und zeigte keine Kreuzreaktivität mit 
anderen eng verwandten Influenzaviren der HA-Subtypen H1, H2, H6 und H7. Ein 
Antikörperklon (JM7_8) wies eine sehr breite Bindungsspezifität für H5. Darüber 
hinaus konnte neutralisierende Aktivität für zwei Antikörperklone gezeigt werden.  
Die Epitop-Analyse auf membrangebundenen Peptiden führte zur Aufklärung eines 6-
Aminosäure kurzen Epitops, welches innerhalb H5-Influenzaviren hoch konserviert ist. 
Mit einer Kombination aus scFv-Fc-Antikörpern mit humanem bzw. murinem Fc-
Fragment wurde für eine Auswahl an Viren ein H5-Sandwich-ELISA und ein 
membranbasierter Immuno-Dotblot-Assay durchgeführt. Hiermit konnte der Beweis 
erbracht werden, dass mit den isoierten Antikörpern der Aufbau eines schnellen 
diagnostischen Tests möglich ist. In Transmissions- und Rasterelektronenmikroskop 
konnte die spezifische Bindung der Antikörper an die Virusoberfläche gezeigt werden. 
Damit konnte gezeigt werden, dass eine erfolgreiche Immunisierungs- und 
Selektionsstrategie zur Isolierung mehrerer H5-spezifischer Antikörper und zur 
Aufdeckung eines hoch konservierten linearen Epitopes führte, welches für H5-
Influenzaviren spezifisch ist. Diese Antikörper und das Epitop können in 
verschiedensten Anwendungen eingesetzt werden. 
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3 Introduction 
3.1 Influenza and influenza viruses 
Three different types of influenza viruses can be distinguished according to the 
sequence of their nucleoproteins – influenza virus A, B and C. Although all three 
influenza types can infect humans, only influenza viruses of the types A and B cause 
remarkable morbidity and only influenza A viruses have the potential to cause 
pandemics due to their extraordinarily high antigenic variability1. 
Influenza A viruses are subgrouped according to antigenic characteristics of the two 
major viral surface proteins – hemagglutinin (HA) and neuraminidase (NA) and can 
infect a broad range of species, among them mammals, e.g. humans, horses, pigs, 
whales and seals (Fig 1). However, their natural hosts are wild water birds, where 16 of 
the known 17 hemagglutinin subtypes and all 9 neuraminidase subtypes have been 
isolated from.  
 
Figure 1: Host range of influenza A virus with the natural reservoir of influenza A virus. 
Figure according to 
2
, modified 
In their natural hosts, wild water birds, influenza virus infection often is restricted to the 
gastrointestinal tract and causes no or only mild symptoms, whereas in humans 
infection affects the upper respiratory tract with symptoms such as fever, chills, 
headache, sore throat, myalgia, and malaise 1. At rare events highly pathogenic avian 
influenza viruses can develop which often have fatal consequences for the infected 
  Introduction 
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host regardless of the species. Viral pathogenicity and transmissibility are critical in 
establishing a pandemic situation. Reasons for high pathogenicity are numerous and 
discussed in section 2.3. but a fatal result of influenza infection always seems to be a 
misrouted interplay of host organism and influenza virus without clear benefit for the 
pathogen unless high transmissibility supports virus spread. 
Influenza A viruses of subtypes H1, H2 and H3 and neuraminidase subtypes N1 and 
N2 have circulated among the human population. Currently H1N1 and H3N2 as well as 
influenza B viruses are prevalent and can contribute to seasonal influenza outbreaks 3.  
Since the beginning of the last century, humans were faced with four pandemics: in 
1918/19 the so-called Spanish flu (H1N1) - the most devastating pandemic with more 
than 20 - 50 million deaths 1, Asian influenza (H2N2) in 1957, Hong Kong influenza 
(H3N2) in 1968 and, most recently, the H1N1 pandemic in 2009.  
3.1.1 Nomenclature of influenza viruses 
Nomenclature of any influenza virus should follow a system established by WHO Expert 
Committee in 1980according to the genus (type), the species from which the virus was 
isolated (deleted if human), location of isolate (mostly country), the number of the strain 
(i.e. laboratory codes if any), the year of isolation followed by the HA and NA subtypes 
4. For example, an H5N1 influenza virus isolated from swan in Germany in 2006 would 
be A/whooper swan/Germany/R65/2006 (H5N1).  
Due to the continuing evolution and diversification of H5N1 virus (Fig 2), a unified 
nomenclature has been suggested by the WHO5which is regularly updated according to 
the evolution of the virus. Hitherto, there are ten phylogenetic H5N1 clades designated 
0 to 9 which are further divided into second, third and fourth order subclades. Currently, 
some orders of clade 1, 2 and 3 are circulating in Asia and Africa. For example, clade 
2.1.3 in Indonesia, 2.2 in India and Bangladesh, 2.2.1 in Egypt (which further diversified 
in 2.2.1.1 clade and 2.2.1/C group) in addition to 2.3.2 and 2.3.4 are circulating in Asia. 
Figure (2) summarizes the recent diversity of clades 2.1 and 2.2.5. 
            10 
 
Figure 2: Conceptual diagram of ongoing H5N1 evolution until 27th May, 2012 
according to 
5
 
  Introduction 
  11  
3.1.2 Influenza virus and genome structure 
Influenza viruses belong to the family of Orthomyxoviridae, are enveloped viruses of 
80-120 nm in diameter and have a roughly spherical shape. The viral envelope 
contains two glycoproteins (HA and NA) and an ion channel protein (M2), all anchored 
in the lipid membrane of the virus. Viral RNA and its protecting and stabilizing proteins 
are organized in the central core of the virus. The M1 protein forms an inner circle 
protecting the viral ribonucleoprotein complex (vRNP). Influenza viruses possesseight 
segments (PB2, PB1, PA, HA, NP, NA, M and NS)of single stranded, negatively 
orientated RNA packed into ribonucleoprotein complexes (vRNP) encoding at least 
eleven viral proteins are encoded: the three surface proteins hemagglutinin (HA), 
neuraminidase (NA) and ion channel protein (M2), and the so-called internal poteins 
nucleoprotein (NP), M1 protein, NEP protein, non-structural proteins NS1 and PB1-F2, 
polymerase acidic protein (PA) and polymerase basic proteins PB1, PB2 1 (Fig. 3). 
Each RNA segment consists of a coding segment flanked by a non-coding sequence at 
its 3‘ and 5‘ end of which the 12 – 15 terminal nucleotides are highly conserved among 
the eight RNA segments. Among all RNA viruses only influenza viral RNA is transcribed 
in the nucleus of the host cell and not in the cytoplasm 6. The viral nucleoprotein is one 
of the most conserved proteins among all influenza viruses7 whereas the two major 
surface proteins hemagglutinin and neuraminidase are highly variable between the 
different subtypes but, in the case of HA, also within the same subtype8. 
 
Figure 3: Schematic view of an Influenza virus 
Viral surface proteins hemagglutinin (HA), neuraminidase (NA) and the ion channel protein (M2) are 
anchored in the viral membrane. The M1 protein foms an inner layer and binds the viral ribonucleic 
complexes (vRNPs) consisting of segmented viral RNA each associated with viral polymerase complex 
(not depicted) and the nucleoprotein (NP). Picture adapted from 
9
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Using reverse genetics, a complete influenza virus can be constructed on the basis of 
cDNA 10 and this technique has been widely employed to investigate the contribution of 
each protein to the viral phenotype6. 
The influenza genome exhibits a huge variability and plasticity leading to continuous 
adaptation to the host, an efficient escape of host immune responses and the 
acquisition of properties that allow the virus to infect new hosts.  Two major 
mechanisms contribute to the genetic variability – antigenic drift and antigenic shift. 
Whereas antigenic drift is described as a slow change in the antigens on the viral 
surface over time driven by the high error rate (1 misincorporated nucleotide per 10,000 
nucleotides) of the viral RNA-dependent RNA-polymerase (vRdRp)11, antigenic shift is 
a rapid change of antigens caused by a recombination of viral RNA segments in a host 
with concurrent infection of at least two different influenza viruses 12. Such genetic 
rearrangements may give rise to viruses with pandemic potential since they can acquire 
the ability to infect new hosts or cause fatal infection due to a lacking immune response 
of the host.  
3.1.3 Infection cycle of influenza viruses 
The influenza virus infection process is initiated by the binding of viral hemagglutinin to 
host cell surface proteins terminated by an α-linked-N-acetylneuraminic acid residue 
(―sialic acid receptor‖)13. Following the attachment,the virus is endocytosed by a clathrin 
mediated pathway 14and acidic milieuwithin the endosome leads to two effects on the 
virus –major conformational changes of the viral hemagglutinin and acidification of the 
inner viral space by proton influx through the M2-ion channel protein. Both processes in 
turn lead to the fusion of viral and endosomal membranes and to the release of viral 
RNA into the cytosol. Viral negative-stranded RNA segments are transported to the 
host cell nucleus, transcribed into mRNA and translated into viral proteins using host 
cell translation machinery. Transcription is associated with a cap-snatching mechanism 
resulting in chimeric mRNA-molecules possessing a polyadenylated host-derived cap 
that are transported into the cytosol and translated 15. Replication and translation 
associated proteins re-enter the nucleus to be packed with viral genomic RNA 
replicated by the vRdRp to form RNPs which in turn, with the help of viral proteins M1 
and NS2, are transported back to the cytoplasm. Progeny virions are released through 
a budding process and the sialidase activity of the viral neuraminidase that cleaves off 
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sialic acid moieties from the viral and host cell surface to prevent accumulation of 
virions at the cell surface. New influenza viruses are set free and can start a further 
infection cycle(Fig 4). 
 
Figure 4: Life cycle of influenza virus and antiviral targets 
1) attachment 2) endocytosis 3) endosomal acidification 4) uncoating of viral RNA and eclipse from 
endosome 5) replication and transcription of viral RNA in the host cell nucleus 6) virus assembly 7) 
budding of progeny viruses. Picture adapted from 
16
 
 
3.2 Influenza hemagglutinin 
3.2.1 Structure of the influenza hemagglutinin 
The hemagglutinin is one of three surface proteins of influenza viruses. It is a 
homotrimeric glycoproteinanchoring in the virus membrane with a transmembrane 
domain and can structurally be divided into a membrane distal globular head-like 
structure comprising a receptor binding site per monomere and most of the antigenicity 
determining epitopes, and a membrane anchored stem-like structure rich in α-helices17. 
A total of 17 subtypes are known. HA 1-16 were isolated from wild water birds, and only 
recently H17 was isolated from bats18.The 16 subtypes exhibit a broad inter- and intra-
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subtype variability. According to antigenic characteristics (ability to react with subtype 
specific hyperimmune sera 19,20 and amino acid sequence homologies (40 – 80 % 
sequence homology between different subtypes and ~ 90 % sequence identity within 
the same HA-subtype 21,22) hemagglutinin subtypes are classified. 
The hemagglutinin monomer is synthesised as an inactive precursor protein (HA0) 
which is proteolytically cleaved at a membrane near cleavage site for activation. Upon 
cleavage the hemagglutinin molecule is divided into two disulphide linked chains – HA1 
with 328 amino acids in length and the HA2 stalk like structure with its 221 amino acids  
for H523. 
Three main structural and functional characteristics of the influenza hemagglutinin have 
been elucidated: i) the receptor binding site at the tip of the globular head domain is 
responsible for host and cell specific attachment of the virus 24; ii) at least four antigenic 
varible regions in the head-like part of the molecule help the virus to escape from host 
immune response 25; iii) the cleavage site at the stalk-like membrane part of the 
molecule must be cleaved to completely acitvate the hemagglutinin, expose amino 
acids needed for the fusion of host and viral membranes to release viral RNA into host 
cell cytosol 24. At least four antigenic sites have been determined 26 and are prone to 
amino acid variations to escape from host immune response. 
The 17 HA subtypes discovered up to now can be divided into three groups as shown 
in Fig. 5; the H17 subtype only discovered recently has low sequence homologies with 
the longer known HAs and seems to represent an own group. The 16 remaining HA 
subtypes are grouped into five clades (H1a, H1b, H9, H3, H7) according to Medina & 
García-Sastre 27 and show three major structural differences i) in those regions of the 
hemagglutinin molecule that refold upon membrane fusion, ii) comprise a different 
orientation of the globular head region in relation to the central trimeric coiled-coil 
portion of the hemagglutinin molecule 28,29 and iii) cap forming residues of the HA2 
subunit leading to the termination of the central trimeric coiled-coil structure 30,31. 
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Figure 5: Classification and structure of influenza A virus hemagglutinin 
a) Classification of influenza viruses into groups according to their antigenic properties is 
depicted. The two major groups are further subdivided into five clades(H1a, H1b, H9, H3, H7) 
and 16 subtypes; classification according to
27
. b) The monomeric structure of influenza 
hemagglutinin with its HA1 head-like structure (blue) comprising the antigenic sites and the 
receptor binding domain (shown by the arrow) and the HA2 stalk-like part (blue) with the 
cleavage site shown as fusion peptide is depicted. Picture adapted from 
32
 
 
3.2.2 Functions of the influenza hemagglutinin 
Influenza hemagglutinin exhibits two major functions essential in the first step of virus 
infection: i) Attachment of the virus and ii) release of virus RNA from host endosomes 
into the cytoplasm after fusion of host endosomal and viral membranes.  
Attachment of the virus 
The binding affinity of influenza hemagglutinin to the host cell surface sialic acid 
receptor facilitates the attachment of the virus to host epithelial cells of the respiratory 
and gastro-intestinal tract – the major transmission route for influenza viruses 33. 
Human and avian influenza viruses show major differences in their tissue tropism 
according to remarkably different host cell receptor recognition patterns. Avian 
influenza viruses preferably bind to sialic acid receptors linked to α2,6-galactose in 
glycosidic binding present on epithelial tissues of the gut and the lungs 34. In contrast, 
the hemagglutinin of human influenza viruses has a higher affinity to α2,3-linked sialic 
acid receptors 35 predominantly present on non-ciliated human airway epithelial cells 36. 
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However, restriction of α2,3- linked receptors to human epithelial cells and α2,6-linked 
ones to avian cells is not exclusive as minor amounts ofα2,6-linked sialic acid can also 
be found on ciliated human epithelial cells and α2,3- linked receptors are present on 
chicken cells 37,38. Pigs and quails express both types of galactose linkage to sialic acid 
receptors on their cells of the respiratory tract in sufficient amounts. Hence, they can 
more easily be infected with influenza viruses adapted to human and avian tissues. 
Pigs and quails are therefore regarded to be ―mixing vessels‖ for influenza viruses as 
was demonstrated in the emergence of the H1N1 pandemic virus in 2009 39–41. 
Chickens also possess both receptor types – although preferentially in different organs 
and tissues 38. 
Cleavage and membrane fusion 
As the cleavage site of influenza hemagglutinin can either be very short (low 
pathogenic influenza viruses) or extended by an insertion of a variable amount of basic 
amino acids (highly pathogenic influenza viruses) the cleavage occurs either at the 
surface of the host cell after virus attachment by trypsin-like proteases or inside the cell 
by furin-like proteases or other proprotein convertases, respectively 42,43. Cleavage and 
protonation of the hemagglutinin precursor lead to major conformational changes     
(Fig. 6). 
 
Figure 6: Conformational changes of the influenza hemagglutinin during the membrane fusion 
process 
Figure according to
44
 
3.3 Pathogenicity and virulence determining factors 
The pathogenicity of influenza viruses is a multigenic issue and is considered to be the 
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result of different viral and host factors. In a plenty of studies it has been shown that 
mutations in many of the viral proteins including HA, NA, NS1, PB2, PB1-F2 contribute 
to viral  adaptation to humans and that several host factors may facilitate infection 
of new hosts (e.g. humans) with influenza viruses (reviewed in 45,46). Due to its 
functions in the first steps of infection the influenza hemagglutinin is suggested to play 
a major role in host restriction of influenza viruses 47–49. Avian influenza viruses per se 
are not adapted to humans. After infection and replication the release of progeny 
viruses is the third process mainly driven by neuraminidase activity that needs host 
adaptation. Furthermore, intraspecies transmissibility of influenza viruses within a 
population of the new host must be guaranteed to establish an endemic situation. 
Tremendous efforts in elucidation of host-viral interplay have been taken during the last 
decades and the contribution of the changing nature of influenza viruses to the 
emergence of pandemic strains has recently been reviewed 50. 
For all surface proteins, especially hemagglutinin and neuraminidase, glycosylation 
patterns seem to have an important impact on immunogenicity in the way that altered 
glycosylation positions may shield antigenic sites from host immune system and thus 
help to evade host immune responses and increase pathogenicity 51–53.  
Certain antigenic sites of the hemagglutinin involved in the alteration of pathogenicity 
have been identified (Fig 7). The viral hemagglutinin shows adaptive mutations in its 
receptor binding sites from avian receptor to human receptors types. Mutations at 
positions 222, 224 as well as 182, 190 and 192 have been shown to be involved in 
receptor type switching54. Up to now, infections of humans with H5 avian influenza 
viruses have remained restricted to single cases with very close contact to infected 
birds. A recent study showed that four substitutions conferred respiratory droplet 
transmission in a ferret model for a reassortant consisting of the mutated H5 and the 
H1N12009 pandemic virus background 55. Here, for the first time a transmission of a 
(yet lab-made) influenza virus with a highly pathogenic H5 hemagglutinin within a 
mammalian species has been demonstrated. Highly pathogenic H7N7 influenza viruses 
caused an outbreak in poultry in the Netherlands in 2003 that led to massive culling of 
poultry to restrict the transmission of the infection. For this virus it was demonstrated 
that an alanine to threonine substitution at position 143 of the hemagglutinin resulted in 
a change in location of infection from upper to lower respiratory tract by attachment to 
bronchial epithelial cells56.  
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The cleavage site is another viral pathogenicity 
factor located in the viral surface protein 
hemagglutinin. In contrast to the single arginine 
representing the cleavage site of low pathogenic 
influenza viruses highly pathogenic variants show 
an insertion of basic amino acids of variable 
length. The amino acid composition of this 
cleavage site determines the localization of the 
infection as a single arginine cleavage site is 
cleaved by local trypsin-like proteases restricted to 
the respiratory and gastrointestinal tracts 
representing the site of first host-virus contact 
resulting in a localized infection57,58.  
Figure 7:Comparison of 
positively selected vs antigenic 
sites of the influenza 
hemagglutinin H3 
In contrast multibasic cleavage sites require furin-like proteases that are ubiquitously 
distributed among different tissues, associated with the trans-Golgi-network of the 
cells59. Viruses with this type of cleavage site may provoke a systemic infection with 
often severe illness or fatal result. Glycosylation sires near the cleavage site can hinder 
or promote cleavage of he HA precursor protein by host proteases and thus contribute 
to the degree of pathogenicity60. 
Several other viral proteins contribute to pathogenicity. The length of the 
neuraminidase stalk region is variable depending on the virus isolate, yet a shorter stalk 
region results in a reduced acessibility of the substrates, sialic acids, seems to be 
associated with a decrease in virus release and hence reduced pathogenicity 61–63. 
Nevertheless, highly pathogenic H5N1 avian viruses isolated from domestic poultry and 
wild birds in China (representing the so-called ‖genotype Z‖ of H5N1 avian influenza 
viruses now endemic in southern China) as well as the H5N1 virus that caused the 
1997 Hong Kong pandemic had a shortened stalk-region in line with obvious high 
pathogenicity64. In parallel to the hemagglutinin, amino acid substitutions in the 
neuraminidase have been shown to cause increased pathogenicity 65. Other proteins 
like M2 (ion channel protein), different proteins of the viral polymerase complex and 
also NS1 are of clear importance in modifying  pathogenicity 66–68. 
Figure 7: Comparison of positively 
selected vs antigenic sites of the 
influenza hemagglutinin H3 
Crystal structure of a H3N2 virus was 
used according to
243
; left in red: amino 
acid positions with positive selection; 
right: the four antigenic regions A 
(red), B (yellow), C (green), D (blue). 
Picture adapted from
244
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3.4 Avian influenza viruses of the H5 subtype – outbreaks and lineages 
Influenza viruses are wide spread among birds and hemagglutinin subtypes 1-16 can 
be found in the orders Anseriformes and Charadriiformes8. Grouping of influenza 
viruses into low and highly pathogenic avian influenza viruses (LPAIV and HPAIV, 
respectively) is based on viral pathogenicity measured in chickens. A small subset of 
influenza viruses has shown high pathogenicity in line with high mortality in domestic 
poultry as well as in wild birds and has proven to be able to cross species barriers and 
infect humans. In 1997, the first human fatal cases due to an infection with a highly 
pathogenic H5N1 virus were observed. This virus originated from sick geese in the 
chinese province Guangdong and was first isolated in 1996 69. 
A/Goose/Guangdong/1/1996 (H5N1) is regarded to be the origin of the ongoing 
panzootic evolution of H5N1 influenza viruses in Asian countries since 1997. Several 
outbreaks among industrial poultry flocks as well as among different wild birds 70,71 and 
re-current infections of humans underline the imminent threat to human health and 
industrial poultry production. Genetic and antigenic variability of the pool of circulating 
and already endemic highly pathogenic H5N1 viruses in Asia sheds light on its 
tremendous adaptive potential and the high risk for a new influenza pandemic. ―Mixing 
vessels‖ like pigs and quails live in close contact to humans and poultry in those 
countries of ongoing H5N1 virus evolution and thus provide an excellent basis for 
further development, reassortment and spread, although low susceptibility of domestic 
pigs to HPAIV H5N1 was observed 72. 
Based on the Guangdong virus isolate, the WHO proposes a hierarchical decimal 
numbering classification of clades and subclades of the emerged highly pathogenic 
H5N1 avian influenza viruses 73. 
3.5 Tools and methods for detection of influenza viruses and influenza virus 
infection 
Virus isolation and propagation is performed in embryonated chicken eggs (ECE) or in 
cell culture. ECE is the most common used system worldwide for obtaining replication-
competent virus and considered to be the gold standard procedure for isolation and 
propagation of AIV74. However, it is laborious, expensive, time-consuming and 
increases the risk of biohazard contamination in case of HPAIV H5N1 75–78. Most 
commonly used cell cultures are Madin-Darby canine kidney (MDCK), primary chicken 
embryo kidney (CEK), primary chicken embryo fibroblast (CEF) cells 77. Less often 
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used cell lines are duck fibroblasts, mink lung epithelial cells and quail fibroblasts79. 
Addition of trypsin to tissue cultures is pivotal for the isolation of LPAIV in contrast to 
HPAIV which are able to grow with or without additional trypsin 80.  
Detection of influenza viruses is generally based on three different target groups: i) 
viral antigens (surface or internal proteins) , ii) viral RNA or iii) antibodies directed 
against different influenza proteins. To detect viral antigens (especially HA, NA matrix 
protein and NP)three different methods have been established and have been 
successfully applied: Lateral Flow Devices 75,81–83, Antigen-Capture Enzyme Linked 
Immunosorbent Assay ( AC-ELISA) 84–86, Immunohistochemistry (IHC) 87–90. 
Surveillance of influenza evolution and the rapid identification and subtyping of a 
potential pandemic influenza virus strain require fast, specific, sensitive and cheap 
techniques 91,92. Recently developed viral RNA detectiontechniques involve the 
reverse transcription polymerase chain reaction (RT-PCR) 93–96, real-time RT-PCR (RT-
qPCR) 75,91,97,98, Nucleic Acid Sequence Based Amplification (NASBA) 99–102, DNA 
microarrays 103–106 and sequence analyses 107,108 fundamentally contribute toAIV 
surveillance and characterization. Antibody detectionplays a critical role in AIV 
surveillance and vaccine development109. Serological assays are inexpensive 
surveillance tools. Agar Gel Precipitation Test 96,110, Hemagglutination Inhibition and 
ELISA 96,111–114 are commonly used tests for AI antibody detection, with ELISA being 
the most sensitive test 75,84,115, whereas the HI test ismore specific in detecting AIV 
antibodies 116,117. HI is a simple but laborious test based on the fact that antibody bound 
hemagglutinin (soluble or bound to the viral surface) fails to agglutinate as long as 
antibody binding interferes with the receptor binding activity of the hemagglutinin. HI is 
used in diagnosis and subtyping of AIV viruses (antigen and/or antibodies), with a panel 
of subtype-specific antisera or antigens/viruses representing all AIV subtypes to identify 
subtype-specific anti-AIV antibodies in different samples like serum, plasma, or egg 
yolk from different species 118. Due to the variability of influenza hemagglutinin, the 
antigen used must be updated according to the field virus particularly for evaluation of 
post vaccination immune response 119–122. 
3.6 Influenza therapy - Antivirals and influenza vaccines 
Therapy of influenza virus infection in humans is based on antivirals that inhibit two 
different influenza virus proteins – the M2 ion channel protein and viral neuraminidase 
(Fig 4). In contrast to influenza specific antivirals Ribavirin inhibits RNA polymerases of 
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different RNA viruses. 
3.6.1 Inhibitors of influenza ion channel protein M2 
These M2 inhibitors are collectively referred to as adamantanes.Amantadine and 
rimantidine, first approved by the US FDA in 1967 and 1993, respectively, belong to 
this group of antivirals and block membrane bound viral ion channel protein M2 123, thus 
preventing acidification of internal parts of the virus and release of viral DNA 124. This 
inhibition occurs by binding of the hydrophobic adamantane drug to hydrophobic 
residues lining the pore in the outer regions of the M2 channel. Adamantanes are not 
active against M2 proteins of influenza B viruses because polar residues line M2 ion 
channel protein in the drug binding parts of the protein 125. Consistent with these 
findings adamantane resistant escape mutants show polar amino acid residues at 
positions critical for drug binding instead of hydrophobic residues 126. An increasing 
resistance of influenza A viruses to adamantanes limit the therapeutic potential of these 
antivirals. Already in 2005 the incidence of amatadine resistance was about 92 % in the 
US127. 
3.6.2 Neuraminidase inhibitors (NAI) 
NAI reduce or abolish release of influenza viruses from infected cells by blocking the 
sialidase function of viral neuraminidase. Progeny viruses stay attached to cell surface 
sialic acid components and are not set free for a new infection cycle. These antivirals 
were designed to be structurally similar to host cell sialic acids and are active against 
influenza A and B viruses. Two different drugs group into NAI: oral drug oseltamivir 
(Tamiflu®, Roche) and inhaled drug zanamivir (Relenza®, GlaxoSmith-Kline), both 
approved by the US FDA in 1999. Both drugs have been demonstrated to be effective 
in prophylaxis and treatment of influenza infection 128,129, but increased resistance to 
NAI becomes a problem. In 2008 nearly 100 % of the seasonal H1N1 virus isolates 
were oseltamivir-resistant without a loss of virulence in these resistant isolates and 
resistance conferring mutation seems to be transmitted without selective pressure upon 
drug use since highest resistance levels have been found also in countries with low use 
of oseltamivir 130. 
3.6.3 Vaccination 
Vaccination programs in animals against highly and low pathogenic avian influenza 
viruses were initiated to prevent development of disease signs as well as to reduce 
mortality, decrease virus shedding into the environment, increase resistance of the host 
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to infection, limit bird-to-bird transmission and reduce losses in the egg production 
131,132. Furthermore, establishing a pre-immunized population to reduce the pandemic 
threat are main intentions of human seasonal influenza vaccination as well as animal 
HPAIV vaccination programs. Extensive vaccination programs have been shown to 
induce antigenic drift of influenza viruses 133,134;they may mask influenza infection of 
poultry flocks and interfere with serological surveillance135–137. Silent spread of influenza 
viruses in a vaccinated flock remains a problem since a 90 % protection of flock 
individuals due to vaccination only lead to a 50 % reduction in outbreak probability 138. 
Inactivated whole virus vaccines and recombinant vaccinesare the two main 
groups of influenza vaccines used135. Inactivated homologous H5N1 vaccineswere 
genetically modified by reverse genetics to remove the multibasic cleavage site in the 
HA protein 139. The major disadvantage of this strategy can be overcome by the use of 
inactivated heterologous vaccinesthat have the same HA subtype as the field virus 
but have a heterologous neuraminidase protein.Nevertheless, due to the antigenic drift 
of the virus afrequent update of the vaccine is required 120,140,141.Recombinant 
vaccinesbased on e.g.Fowl Poxvirus142, Infectious Laryngotracheitis virus 143 or 
Newcastle Disease virus 144–146 have been used as vectorscarrying one or more 
influenza virus genes. However, antigenic matching of the vaccine to the currently 
circulating viruses is critical147. Vaccinated animals are discriminated from infected 
individuals by the detection of antibodies directed against influenza virus proteins not 
used in the recombinant vaccine virus and exclusively produced by influenza infected 
animals.  
 
3.7 Antibodies 
Immunoglobulins (Ig, antibodies) are the major players in humoral immune response of 
the adaptive immune system and are broadly applied in research, therapy and 
diagnostics. 
Antibodies exert two different functions associated with the amino- and the 
carboxyterminal regions of the molecule. The highly variable aminoterminal region 
facilitates binding of the so-called antigen (viral or bacterial proteins, other molecules) 
and the highly constant carboxyterminal region of the antibody activates effector-
mechanisms such as opsonizing and activation of the complement dependent 
cytotoxicity (CDC) and the antibody dependent cellular cytotoxicity (ADCC) 148. Thus, 
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antibodies structurally link acceptor and effector function within a single molecule. 
Antibody response is initiated through antigen contact and human antibodies are built in 
the B-cells of the human lymphatic system.  
The general structure of an antibody molecule described herein is based on human Ig 
molecules (Fig 8 a). The antibody consists of two identical heavy polypeptide chains 
(MW 50,000 Da each) and two identical light polypeptide chains (MW 25,000 Da each) 
forming a Y-shaped heterotetramer through disulphate bridges. The so called hinge 
region connects the two heavy chains to each other involving also additional covalent 
and non-covalent bonds. Two different classes of light chains are known: κ and λ, with 
the κ –chain being more dominant in the human antibody repertoire 149. According to 
the constant regions of the heavy chains five isoforms of immunoglobulins (IgA, IgD, 
IgE, IgG, IgM) with different functions in antigen neutralization and opsonization and 
complement activation, can be distinguished. Depending on the isoform and the degree 
of multimerization antibodies have a molecular weight in the range of 150 (IgG) to 940 
(IgM) kDa 150. The chemical structure of antibodies was elucidated for the first time by 
Porter and Edelman in 1964 and both were awarded the Nobel Prize for this work in 
1972. With about 80 % of the overall serum immunoglobulins affinity maturated IgG are 
the most abundant Igs in humans produced following an IgM-based primary response 
148. 
Antibody chains are composed of so-called immunoglobulin domains – each consisting 
of about 110 amino acid long repetitive sequences with four or two of them building up 
the heavy or light chain, respectively. Light chains consist of one variable and one 
constant domain, whereas heavy chains comprise one variable and three constant 
chains. The aminoterminal domain of each chain is characterized by a considerable 
high variabiliy with three hypervariable regions of 3-20 amino acids – the CDRs 
(complementarity determining regions) and the more or less constant framework 
regions flanking the CDRs 151,152. The six CDRs of the heavy and the light chain form 
the antigenic binding site and each antibody posesses two of them conferring binding of 
the antigen through hydrogen bonds, Van-der-Waals forces and ionic bonds 148. 
3.7.1 Antibody formats 
Different antibody formats can be obtained from proteolytic cleavage with papain and 
pepsin and using recombinant methods. While pepsin cleaves the antibody in its hinge 
region leading to a bivalent F(ab)2 fragment, papain activity divides the antibody into 
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two Fab-fragments (light chain and variable and first constant domain of the heavy 
chain covalently linked to each other) and the Fc-fragment 153.Recombinant antibody 
formats are widely used in diagnostics and therapy and have advantages e.g. smaller 
size, better tissue penetration, lack of complement activation due to the absence of the 
Fc-part 154–156 but also potential disadvantages as faster renal clearance and often – at 
least for scFv antibodies - reduced stability compared to full size immunoglobulins. 
Different recombinant antibody formats are used (Fig 8) with the scFv antibody 
representing the smallest antibody format consisting of the variable heavy and the 
variable light chain connected by a peptide linker, the Fab fragment with the variable 
and first constant domain of the light and the heavy chain covalently linked to each 
other and the bivalent scFv-Fc antibody with two scFv antibodies linked via a flexible 
region mimicking the hinge region to an Fc-fragment. This bivalent construct helps to 
overcome the frequently reported lower stability of single-chain scFv antibodies 157, 
increases avidity by dimerization of the scFvs, allows additional effector functions and 
facilitates detection via the Fc-part. Furthermore, by linking recombinant antibodies to 
effector molecules such as toxins, proteases, RNases or other drugs a site directed 
drug targeting can be achieved and is under broad investigation (158,159). 
 
Figure 8: Antibody formats 
a) Schematic view on the general structure of an immunoglobulin. The Y-shaped antibody consitsts of 
two heavy and two light chains that are connected by disulphate bonds in the hinge-region. The 
variable domains of both chains contribute to the antigen binding site.B) single-chain Fv antibody, c) 
Fab fragment, d) scFv-Fc antibody 
154
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3.7.2 Chicken antibodies 
Generally, chicken posses different immunoglobulin isotypes which are structurally and 
functionally related to human antibodies: IgM as the primary antibody response, IgA 
dominating immunoglobulins in body secretions and IgG (mostly referred to as IgY 160 
due to structural differences compared to human IgG) representing the major isotype in 
serum and in egg yolk (reviewed in 161). Passive immunization through maternal hen-
derived IgY immunoglobulins in the egg yolk is a special characteristic of ovipar  
animals possessing IgY antibodies.  
Beside the functional and structural similarities IgG and IgY (Fig 9) striking differences 
have to be mentioned as well: IgY antibodies possess four constant heavy (CH1-CH4 ) 
domains compared to the three CH-domains of the human IgG,  
and lack the hinge region which is not 
surprising and consistent with the hypothesis, 
that the hinge region is the result of a 
condensed CH2-region 
162. IgY-antibodies show 
a decreased ability to precipitate antigens and 
exert notable skin sensetizing action that can 
mediate anaphylactic reactions 163,164 similar to 
human IgE. Disulfide bonding patterns are 
similar in IgY and primate IgE 165. The chicken 
immunoglobulin repertoire is built in the bursa 
Fabricii, a mainly embryonic organ that starts 
to degenerate several weeks after hatching 
and is a remnant without function in 2-years old 
chickens 166. 
Figure 9: Structure of chicken IgY compared to 
human IgG antibodies. 
The truncated IgY version present in some animals is shown as IgY(Fc)and possess only two CH-
domains, picture from
161
 
In contrast to the diversity of V, J and D gene segments in the light and heavy chain 
locus known for humans, chickens have only one heavy chain (VH) and one light chain 
(VL) with only one functional V and J gene segment for each of them. Several 
pseudogenes (ψ) upstream of the VH and the VL gene segment (100 for VH and 25 for 
VL) - lacking recombination signal sequences and promoter region - serve as gene 
reservoir for the diversification of the chicken antibody repertoir by a process called 
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gene conversion 167–169. CDR3 is encoded by the V-D-JH junction and its variability is 
further increased by a total of 15 DH segments, and single base pair losses or additions 
at the D-segment during the process of gene conversion 168,170,171. Since 100 
pseudogenes contribute to VH chain diversity compared to 25 pseudogenes for VL 
chain, chicken antibody diversity is mainly heavy chain derived. Somatic 
hypermutations as known for human antibodies also contribute to affinity maturation of 
antibodies from the naïve immune repertoire of chickens the generation of which is 
completed several days after hatching. Reduced stability of chicken IgY under mild 
reducing conditions has been described172 as well as a modified hydrolyzation of IgY by 
papain leading to Fab fragments and degeneration of the Fc-fragment to dialyzable 
peptides 173. 
3.8 Antibody phage display 
The phage display technology allows for the selection of specific binders (either 
peptides or antibodies) to numerous antigens which are immobilized to a solid phase. 
These binders are genetically and physically linked to one of the surface proteins of the 
filamentous bacteriophage M13 and thus whole libraries of antigen binding molecules 
can be displayed on the phage surface and stored in a volume as small as a few 
microliters. A schematic view on a phage displaying an scFv antibody and on the 
genetic map of the antibody encoding phage display vector pHAL14 is provided in Fig 
10. Compared to the hybridoma technology, another method to select for antigen 
specific antibodies, the selection process of phage display is performed completely in 
vitro with all possible advantages in designing the selection conditions such as adjusted 
pH-, salt- and temperature conditions, use of toxins as antigens and competitors during 
the selection process, duration of the selection, pre-selection on unfavourable antigens 
and implementation of multiple antigens during selection 174,175. Furthermore, phage 
display is compatible with high throughput technologies thus allowing a rapid screen of 
numerous antigens or libraries 176. An undisclosed freedom in the choice of the antigen 
(as long as it is soluble, immobilizable and of high purity) is the basis for the broad 
applicability of the phage display technology. 
  Introduction 
  27  
 
Figure 10: Schematic view on a phage displaying an scFv and the genetic map of the phage 
display vector pHAL14. 
a) a phage presenting an scFv-antibody fused to pIII-protein, the five phage coat proteins pIII, pVI, pVII, 
pVIII and pX and, the phagemid DNA encoding the scFv sequence (red) and b) the phage display 
vector pHAL14 including an scFv; cloning sites, promoter (Lac Pr), ribosomal binding site (RBS), 
secretion leader peptide (pelB), ampicillin resistence gene (bla) and the two origins of replication (colE1 
and M13 ori)
177
. 
Described for the first time in 1985 as peptide phage display with the genetic 
information for the peptide incorporated into the phage genome 178, phage display has 
overcome initial problems in the expression of antibody displaying phages and has 
become a very effective, successful and broadly used techniques in antibody isolation 
and selection. Using phagemids for encoding the antibody gene fused to the phage 
surface protein along with the E. coli origin of replication, marker genes, a multiple 
cloning site and the origin of replication of the filamentous phage allows the 
autonomous replication of the phagemid DNA within the host cell. A helper phage 
provides the genetic information for phage replication and wild-type phage proteins but 
is replication deficient due to a mutation in the helper phage gene II resulting in an 
increased packaging of phagemid DNA including the antibody-pIII-fusion. Thus, 
basically using phagemids for phage display, the antibody-pIII fusion product is more or 
less monovalently displayed on the phage surface with the wild-type pIII proteins 
derived from the helper phage. This monovalent display is of benefit for the selection of 
high affinity antibodies especially from immune libraries 179, whereas polyvalent display 
of antibodies with the help of a so-called hyperphage has been shown to be of 
advantage in the initial selection round when using naïve antibody libraries 180.All five 
phage coat proteins have been sucessfully used for phage display with pIII-display 
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representing the broadest applied method181. 
During the selection process – the so-called panning (Fig 11) –a solid phase 
immobilized antigen is incubated with the respective phage library follwowed by 
washing steps to remove unbound phages. After an elution step phage recovery is 
performed by infecting E. coli with eluted phages, following an amplification and 
purification of the phages from this first panning round. Within successive rounds of 
pannings stringency and panning conditions can be adapted according to the desired 
properties of the antibody to be selected. 
 
 
Figure 11: Selection cycle applied in antibody phage display (panning) 
Figure adapted from
156
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3.9 Aim of the project 
Despite all efforts influenza remains a constant threat to human health. Seasonal 
influenza causes more than 1 million deaths worldwide 182 and highly pathogenic 
influenza viruses have repeatedly caused devastating outbreaks in industrial poultry 
flocks. Moreover, formerly bird restricted H5N1 influenza viruses have acquired the 
property to cross species barriers and sporadically infect humans (WHO July 2012). 
Virus surveillance remains a demanding issue. Since up to now exclusively influenza 
viruses of the subtype H5, H7 have shown to develop into highly pathogenic influenza 
viruses and avian influenza viruses of the subtypes H5, H7 and H9 have infected 
humans, a subtype specific system for the detection and discrimination between these 
subtypes is highly desirable. 
The aim of this work was to develop H5 specific antibodies toaddress the lack of 
antibody based subtype specific detection systems for H5 influenza. Chickens were 
immunized with phylogenetically different H5 influenza viruses and antibody gene 
libraries were constructed from chicken RNA. The constructed chicken anti-H5 
immune antibody phage libraries as well as naïve human antibody phage libraries 
were used to isolate H5 specific antibodies. Two different recombinant H5 antigens 
from human and avian origin were implemented. Generated antibodies were analysed 
with regard to their binding specificity for H5 and other hemagglutinin subtypes, their 
neutralization and virus detection potential in several assays. 
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4 Material 
4.1 Consumable material 
Material Supplier 
Breathable sealing films for 96 well plates Excel Scientific/ Sigma Aldrich, München 
butvar-coated 300 mesh copper grids Agar scientific, Essex, England 
Culture dishes  
24 well cell culture, polystyrene PAA Laboratories GmbH, Pasching 
cell culture Sarstedt, Nürnbrecht 
Petri dishes Greiner Bio-one, Frickenhausen 
big plates Sarstedt, Nürnbrecht 
Dialysis membranes ViskingType 8/32  
MWCO 14000 
Carl Roth, Nürnbrecht 
Electroporation cuvettes Gene pulser 0.1 cm BioRad, München 
Erlenmeyer flasks, polycarbonate  
with vented caps 
Corning, Karlsruhe 
Filter (celluloseacetate: 0.2 µm; 0.45 µm) Sartorius, Göttingen 
Filtertips (10 µL; 200 µL; 1000 µL) Sarstedt, Nürnbrecht 
Immunoblot filter  Schleicher-Schuell, Dassel 
Kits  
PeqGOLD Plasmid Miniprep Kit I peqLab, Erlangen 
Nucleobond Xtra Midi  Macherey-Nagel, Düren 
Nucleospin Extract II Macherey-Nagel, Düren 
Silver Staining Kit PlosOne™ GE Healthcare 
SuperScript First-Strand 
Synthesis System for RT-PCR 
Invitrogen, Karlsruhe 
Magnetic beads  
Carboxylic beads M270 Invitrogen, Karsruhe 
Epoxy beads M270 Invitrogen, Karsruhe 
Streptavidin beads M280 Invitrogen, Karsruhe 
mica strips SCD500 Bal-Tec, Liechtenstein 
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Material Supplier 
Micro-Schraubröhrchen Sarstedt, Nürnbrecht 
MTP Polypropylene, 96 well, flat bottom Greiner Bio-one, Frickenhausen 
MTP Polypropylene, 96 well, round bottom Sarstedt, Nürnbrecht 
MTP Polysyrole 96 well, Maxisorp NUNC, Wiesbaden 
MTP Polysyrole 96 well NUNC, Wiesbaden 
MTP polysorp, Streptavidin coated NUNC, Wiesbaden 
PVDF menbrane T830.1 Carl Roth, Nürnbrecht 
Pipette tips (10µL; 200 µL; 1000 µL) Sarstedt, Nürnbrecht 
Reaction tubes 1.5 mL; 2 mL Sarstedt, Nürnbrecht 
Serological pipettes  
(2.5 mL, 5 mL, 10 mL, 25 mL) 
Sarstedt, Nürnbrecht 
Spatula sterile VWR, Darmstadt 
Syringes (2 mL, 5 mL) B. Braun; Melsungen 
Syringe Filter, single use, Minisart RC4, 0.45 nm Sartorius, Göttingen 
Tubes polypropylene 15 mL, 50 mL Corning, Karlsruhe 
4.2 Equipment 
Equipment Description Supplier 
Blotting Equipment TransBlot Semi DryTransfer 
Cell 
BioRad, München 
 Multiscreen Mini Protean III BioRad, München 
Protein Purification System Profinia BioRad, München 
Electrophoresis System Biotech. Model 40-0708/40-314 peqlab Biotech GmbH, 
Erlangen 
 Mini Protean III BioRad, München 
Electroporator Micropulser BioRad, München 
ELISA System Reader TECAN Sunrise TECAN, Crailsheim 
 Washer Columbus pro-basic TECAN, Crailsheim 
 TECAN Hydroflex Bead washer TECAN, Crailsheim 
Filter system Bottle top Nalgene, Sartorius 
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Equipment Description Supplier 
Gel documentation Gel documentation Intas, Göttingen 
Incubators BE400 Memmert, Schwabach 
 Thermomixer 5436 Eppendorf, Hamburg 
 Hera Cell Heraeus (with CO2-
supply) 
Ehret GmbH, Emmendingen 
Laminar flow boxes Thermo Scheintific Msc-
Adventage 
 
 Heraeus, Herasafe  
Magnetic bead separator Dynal-MPC Invitrogen, Karlsruhe 
PCR Cycler   
Photometer Nanodrop ND-1000 peqlab Biotech GmbH, Erlangen 
 Biochrom LTB Libra S11 Biochrom, Berlin 
Shakers Multi-Shaker Rotator RS-24 G Kisker 
 Inforr HT Multitron Infors AG, Bottmingen, Schweiz 
 Certomat BS-1 B. Braun Biotech, Melsungen 
 Infors HT Minitron (with CO2 
supply)  
Infors AG, Bottmingen, Schweiz 
 MTP-shaker Thermoshaker 
PST 60 HL-4 
Lab 4you, Berlin 
Scales Sartorius excellence 1203 MP Sartorius, Göttingen 
 EMB 220-1 Kern, Balingen-Frommern 
Vortex   
Centrifuges Eppendorf 5810R Eppendorf, Hamburg 
 Eppendorf 5415D Eppendorf, Hamburg 
 Sorvall RC5B Plus Kendro, Hanau 
 Sorvall RC6 Plus Kendro, Hanau 
 Heraeus Multifuge 3 S-R  
Electron microscopy 910 TEM  Zeiss, Oberkochen, Germany 
 DSM982 Gemini field emission 
scanning electron microscope  
Zeiss, Oberkochen, Germany 
 In-lens SE-Detektor Zeiss, Oberkochen, Germany 
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Equipment Description Supplier 
 Everhart-Thornley SE-detector Zeiss, Oberkochen, Germany 
 Slow-Scan CCD-Camera 
(ProScan, 1024x1024) 
Scheuring, Germany 
4.3 Chemicals 
Used chemicals were supplied, except as noted otherwise, by Fermentas (St. Leon Rot), 
Merck (Darmstdt), Roche (Mannheim), Carl Roth (Karlsruhe), Sigma Aldrich (Fluka, Riedel 
de-Haen) and had p.a. quality. 
4.4 Buffers, media and solutions 
All buffer, media and solutions were prepared, except as noted otherwise, in ultrapure water. 
Media were autoclaved prior use and thermolabile components were filtered and added 
under sterile conditions. 
Declaration Components Concentration 
General buffers and solutions   
PBS NaCl 
NaH2PO4xH2O 
Na2HPO4xH2O 
145 mM 
7.5 mM 
2.5 mM, pH 7.4 
Gycerol Glycerol 80% (v/v) 
Tween 20 Tween 20 0.05% (v/v) 
Affinity chromatography Protein A (Profinia), working formulations 
Binding buffer/Desalting buffer 
pH 7.0 
NaCl 
KCl 
Na2HPO4  
KH2PO4 
137 mM 
2.4 mM 
4.3 mM 
8.5 mM 
Binding buffer (high salt) NaCl 
KCl 
Na2HPO4  
KH2PO4 
2 M 
2.4 mM 
4.3 mM 
8.5 mM 
Elution buffer pH 3.0 Citric acid 
Sodium acetate 
100 mM 
100 mM 
Cleaning buffer 1, pH 8.0 NaCl 
Tris 
500 mM 
50 mM 
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Declaration Components Concentration 
Cleaning buffer 2, pH 4.4 NaCl 
Sodiumacetate 
500 mM 
100 mM 
Storage buffer Benzylalcohol 2 % (v/v) 
CIP buffer affinity column NaOH 0.1 M 
Agarose gelelectrophoresis 
Agarose agarose 0.8-1.5% (w/v) 
Ethidiumbromide solution   
Loading buffers   
X-buffer 6x Tris-HCl pH 7.6 
xylene cyanol FF 
glycerol 
EDTA 
10 mM 
0.03% (w/v) 
60% (v/v) 
60mM 
B-buffer 6x Tris-HCl pH 7.6 
bromophenol blue, 0.03% 
glycerol 
EDTA 
10 mM 
0.03% (w/v) 
60% (v/v) 
60mM 
Running buffer TAE pH 8.0 Tris HCL 
Acetic acid 
EDTA 
4 mM 
2 mM 
1 mM 
Coomassie Staining 
Staining solution Comassie Brilliant blue GLR-
250 
Acetic acid 
2-propanol 
0.05% (w/v) 
 
10% (v/v) 
25% (v/v) 
Destaining solution Acetic acid 10% (v/v) 
Coupling to magnetic beads   
Carboxylic beads   
NHS NHS 0.1 M 
EDC EDC 0.5 M 
Sodium acetate solution  
pH 5.0 
sodium acetate 10 mM 
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Declaration Components Concentration 
Ethanolamine-HCL  
pH 8.5 
Ethanolamine-HCL 50 mM 
Epoxy beads   
PBS, pH 7.4 PBS  
Borate buffer pH 8.6 sodium borate 100 mM 
Streptavidin beads   
PBS, pH 7.4 PBS  
Cultivation of bacteria   
dYT culture medium Bacto-yeast extract 
Bacto-tryptone 
NaCl 
1.0 % (w/v) 
1.6 % (w/v) 
0.05 % (w/v) 
dYT agar Bacto-Agar in dYT culture 
medium 
1.5 % (w/v) 
dYT-GA dYT culture medium 
Glucose 
Ampicillin 
 
100 mM 
100 mg/L 
dYT-T dYT culture medium 
Tetracyclin 
 
50 mg/ L 
dYT-GAT agar Bacto-Agar in dYT culture 
medium 
1.5 % (w/v) 
Glucose solution Glucose 2 M 
IPTG solution IPTG 1 M 
Mg
2+
 solution I MgCl2 1 M 
Mg
2+
 solution II MgSO4 1 M 
SOC Bacto-Tryptone 
Yeast extract 
NaCl 
MgCl2 
MgSO4 
Glucose 
2.0 % (w/v) 
0.5 % 
0.005 % (w/v) 
10 mM 
10 mM 
20 mM 
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Declaration Components Concentration 
ELISA   
Blocking solution milk PBS 
Tween 20 
milk powder 
 
0.05 % (v/v) 
1-2 % (w/v) 
Blocking solution BSA PBS 
Tween 20 
BSA 
 
0.05 % (v/v) 
1-2 % (w/v) 
Washing buffer PBS 
Tween 20 
 
0.05% 
Immobilization buffer pH 9.6 sodium carbonate 50 mM 
Declaration Components Concentration 
Developing solution TMB solution A 
TMB solution B 
95 % (v/v) 
5 % (v/v) 
Stopp solution H2SO4 1N 
Epitope mapping   
T-BST buffer   
CBS buffer   
Developing solution CBS buffer 
MgCl2 
BCIP 
MTT 
 
5 mM  
0.006 % (w/v) 
30 µg/ mL 
Stripping buffer A pH 7.0 Urea 
SDS 
β-Mercaptoethanol 
8 M 
1 % (w/v) 
0,5 % (v/v) 
Stripping buffer B 10 % Essigsäure, 50 % EtOH in 
H2O 
 
MTT solution MTT 5 mg/ mL 
Expression of scFv-Fc antibodies in eukaryontic cells 
Transfection solution PEI 
DMEM 
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Declaration Components Concentration 
DMEM (High glucose) FCS 
Penicillin/Streptomycin 
8 % 
1 % (v/v) 
 
Penicillin/Streptomycin Penicillin/Streptomycin (100x) 1 M 
F17   
F17 complete FreeStyle F17 
glutamine 
pluronic F68 
 
7.5 mM 
0.1 % (w/v) 
Immunoblot   
Blocking solution PBS 
Tween 20 
 
2 % (v/v) 
 
Washing solution PBS 
Tween 20 
 
0.05 % (v/v) 
Incubation solution PBS 
Tween 20 
milk powder 
 
0.05 % (v/v) 
1 % (w/v) 
Transfer buffer Glycine 
Tris HCl 
192 mM 
25 mM 
Developing solutions AP conjugate 
BCIP solution Dimethylformamide 
BCIP 
100 % (v/v)  
1.5 % (w/v) 
NBT solution Dimethylformamide 
NBT 
70 % (v/v)  
3 % (w/v) 
AP-Substrate buffer pH 9.5 Tris HCL 
MgCl2 
100 mM 
0.5 mM 
Developing solutions HRP conjugate 
DAB solution DAB 
PBS 
CoCl2 
25 mg/ mL (w/v) 
 
0.0 2% (w/v) 
H2O2 solution H2O2 37 % (v/v) 
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Declaration Components Concentration 
HRP-Substrate buffer DAB 
H2O2 
2.5 mg/ mL (w/v) 
0.0037 % (v/v) 
IPMA   
Fixation solution methanol 
acetone 
40 % (v/v) 
60 % (v/v) 
Wash buffer  TBS 
Tween 20 
 
0.05% (v/v) 
Staining solution DMF 
AEC 
2.5 mL (100 %) 
1 pellet 
Phage preparation buffers   
Phage Precipitation buffer PEG 6000 
NaCl 
20 % (w/v) 
2.5 M 
 
Phage dilution buffer, pH 7.5 Tris HCl 
NaCl 
EDTA 
10 mM 
20 mM 
2 mM 
PCR   
dNTPs dNTP (Fermentas) 10 mM 
Purification of influenza viruses 
Sucrose gradient I sucrose 60 % (w/v) 
35 % (w/v) 
Tris-buffer Tris pH 7.4 
EDTA pH 7.2 
100 mM 
3 mM 
Sucrose gradient II sucrose 60 % (w/v) 
50 % (w/v) 
40 % (w/v) 
30 % (w/v) 
SDS-PAGE   
Acrylamide solution Acrylamide 
Bisacrylamide 
30 % (w/v) 
0.8 % (w/v) 
APS solution APS 10 % (w/v) 
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Declaration Components Concentration 
Loading buffer 5x (Laemmli) TrisHCl pH6.8 
SDS  
Glycerin 
β-Mercaptoethanol  
Bromophenolblue 
0.312 M 
10 % (w/v) 
50 % (v/v) 
15 % (v/v) 
0,02 %(w/v) 
Running buffer Glycine 
SDS 
Tris HCl 
192 mM 
0.1 % (w/v) 
25 mM 
SDS solution SDS 10 % (w/v) 
Tris HCl-solution pH 6.8 Tris HCl 1.5 M 
Tris HCl-solution pH 8.8 Tris HCl 1 M 
4.5 Bacterial strains, cell lines and viruses 
Bacterial strain Name Properties / Cultivation Supplier 
E. coli XL1-Blue 
MRF‘ 
supE44 hsdR17 recA1 endA1 gyr A46 thi 
relA1lac-F’ [proAB+lac
g
 ZDM15 TN10 (tet
R
) 
Agilent Technologies 
Deutschland GmbH, 
Böblingen 
Cell Line Name Properties / Cultivation Supplier/Reference 
HEK 293T ATCC CRL-
11268 
human embryonic kidney cells, adherent  Sena-Esteves et al, 
1999 
HEK 293-6E  human embryonic kidney cells, growth in 
shaking culture
183
 
 
All influenza viruses were supplied by the FLI and exclusively used in the laboratories of the FLI. 
All influenza viruses were supplied as allantoic fluid supernatant produced in embryonated 
chicken eggs and were not inactivated. 
H/N nomenclature Pathotype Virus strain Supplier 
H5N1 HP A/Vietnam/1197/2004 (NiBrg14) FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
H5N1 LP A/teal/Föhr/Wv632/05  FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
H5N2 LP A/goose/Manitoba/428/06  FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
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H/N nomenclature Pathotype Virus strain Supplier 
H5N1 HP A/Whopper swan/R65/DE06 FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
H5N2 LP A/duck/Potsdam/1402/86  FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
H5N2 LP A/mallard/Ger/Wv476/04  FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
H5N3 LP A/mallard/Ger/Wv1349/03  FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
H5N6 LP A/duck/Potsdam/2216/84  FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
H5N9 LP A/chicken/Italy/22/98  FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
H5N9 LP A/mallard/B.C./544/05 FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
H1N1 LP A/duck/Germersheim/R30/06  FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
H2N2 LP A/guinea fowl/Ger/D23/85  FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
H6N2 LP A/turkey/Germany/617/07  FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
4.6 Recombinant hemagglutinins 
Name Origin Expression 
system 
Supplier 
H5  
A/Anhui/012005(H5N1, HP) 
human insect cells Sino Biologicals GmbH, China 
H5  
A/Canada 
goose/Germany/71/06
184
 
(H5N1, HP) 
avian insect cells FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
H5 
A/chicken/Egypt/0879-
NLQP/2008-R737/09 (H5N1 HP) 
avian insect cells FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
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H7 
A/chicken/Germany/R28/03
184
 
(H7N7, HP) 
avian insect cells FLI, Isle of Riems, Germany,  
Prof. Dr. Harder 
4.7 Plasmides 
Plasmid Application 
pHAL 14 phagemid –vector, construction of antibody-libraries, phage-display 
pCMX2.5-hIgG1Fc-XP eucaryontic expression vector, expression of scFv-humanIgG1Fc-antibodies 
pCMV2.5-mIgG1Fc-XP eucaryontic expression vector, expression of scFv-mouseIgG1Fc-antibodies 
pCSE2.5-mIgG2cFc-XP eucaryontic expression vector, expression of scFv-mouseIgG2cFc-antibodies 
4.8 Oligonucleotides 
Oligonucleotide Sequence 5’-3’ Application 
MHChick VH_f gccgtgacgttggacgagtcc  
MHChick VH-r2 ggttgcactcccggaggagaccatgacttcggtcc 
MHChick VL-f gcgctgactcagccgtcctcg 
MHChick VL-r acctaggacggtcagggttgtc 
MHChick 
VH_NcoI_f 
gtcctcgcaccatggccgccggacgttggacgagtcc  
MHChick 
VH_HindIII_r2 
gtcctcgcaaagctttggggcggatgcactcccggaggag
ac 
MHChick 
VL_MluI_f 
accgcctccacgcgtagcgctgactcagccgtcctcg 
MHChick 
VL_NotI_r 
accgcctccgcggccgcacctaggacggtcagggttgtc 
MhlacZpro_f ggctcgtatgttgtgtgg  
MhgIII_r ctaaagttttgtcgtctttcc  
Tor-pCMV-
mIgG01-FC-seq-f 
cactttgcctttctctcc Amplification of scFv  
pCMV2.5-mIgG1Fc 
pCMX2.5-hIgG1Fc 
pCSE2.5-mIgG2cFc 
Tor-pCMV-
mIgG01-Fc-seq-r 
cagatggctggcaactag 
random hexamer 
oligonucleotides 
 cDNA synthesis 
Oligonucleotides for the amplification of chicken antibody genes were designed by 
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Dr. Michael Hust according to published data185, modified for the antibody gene 
phage display vector pHAL14 and kindly provided. 
4.9 Enzymes 
Enzyme/Buffer Supplier 
BSA 100 x Fermentas 
Calf intestine phosphatase (CIP) Fermentas 
Go Taq DNA polymerase PROMEGA, Mannheim 
Restriction endonucleases Fermentas 
Restriction-buffers NEB 2, 3, 4 Fermentas 
T4 DNA Ligase PROMEGA, Mannheim 
T4 DNA ligase buffer 10x PROMEGA, Mannheim 
Trypsin Sigma, München 
4.10 Antibodies 
Antibody Application/Dilution Supplier 
goat-anti-mouseIgGFc-HRP 
115-035-071 
ELISA/Immunoblot 1:25,000 Dianova 
mouse-anti-C-Myc-tag ELISA/ 1:2000 AG Dübel 
mouse-anti-pIII Immunoblot/1:2000 MoBiTec, Berlin 
goat-anti-humanIgGFc-HRP 
A 0170 
ELISA 
Immunoblot 
 
 
Sigma-Aldrich, München 
goat-anti-mouseIgG Fc specif 
HRP 
A 2429 
Immunoblot/1:10,000 Sigma-Aldrich, München 
goat-anti-human IgG Fc AP 
109-055-098 
 Dianova 
goat-anti-chicken IgG HRP 
A9792 
 Sigma Aldrich, München 
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4.11 Software and databases 
Software/Databases Application Reference 
Vector NTI   
Multalin amino acid alignment of 
antibodies 
 
NCBI Influenza virus resource amino acid alignment of HA  
RCSB protein database Protein structure modelling  
ITEM-Software  TEM/SEM Olympus Soft Imaging 
Solutions, Münster, Germany 
iMol version 0.40 Protein structure modelling  
4.12 Others 
Product Supplier 
DNA ladders:  
Generuler™ 100bp DNA ladder NEB 
Generuler™ 1kb DNA ladder NEB 
Generuler™ 50bp DNA ladder, N3233 NEB 
dNTPs MBI Fermantas, St.Leon-Rot 
Helperphage M13KO7 GE Healthcare, München 
Protein ladders:  
Precision Plus Protein dual colo standard (250-
10 kDa) 
BioRad, München 
Precision Plus Protein unstained standard (250-
10 kDa) 
BioRad, München 
peqGoldIV peqLab, Erlangen 
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5 Methods 
5.1 General methods 
Methods described herein have been applied several times within this thesis. All 
follow a general procedure described with given modifications. 
5.1.1 Preparation of plasmid DNA 
Plasmid DNA was extracted from growing E.coli over night cultures using DNA 
isolation kits from Macherey&Nagel according to manufacturer‘s protocols. For 
elution of DNA provided elution buffer (10 mM Tris, pH 8.0) or H2O was used.  
5.1.2 Precipitation of DNA 
DNA was ethanol precipitated. Ligation samples were filled to a volume of 100 µL 
with H2O. After addition of 10 µL 3 M sodium acetate buffer pH 5.2 and 275 µL 100% 
ethanol the sample was mixed well and incubated for 15 min at room temperature. 
Following a 5-15 min centrifugation at 4 °C and 16,000 xg the DNA-pellet was 
washed twice with 500 µL 70 % ethanol separated by a centrifugation step (5 min, 4 
°C, 16,000 xg). The DNA pellet was air-dried and resuspended in an appropriate 
amount of H2O . 
5.1.3 Purifications of DNA from agarose gels or PCR reactions 
Purifications of DNA from agarose gels or PCR reactions were performed using 
NucleoSpin® Gel and PCR Clean-up Kit (Macherey&Nagel) according to 
manufacturer‘s protocols. 
5.1.4 Determination of DNA-concentration 
Measurement of DNA-concentration was performed using NanoDrop 
spectrophotometer (Thermo Scientific) according to manufacturer‘s protocols. 
5.1.5 Agarose gelectrophoresis 
Gels with an agarose content of 0.8 – 2 % (w/v) and two different loading buffers (B-
buffer and X-buffer) were used depending on expected DNA size. Size of DNA 
fragments was determined using a DNA-standard that was separated on the same 
gelcontaining ethidiumbromide. Separation was performed at 100 – 130 V and 300 
mA. Detection in UV-light (λ = 312 nm). DNA was excised from agarose gels when 
indicated and purified using protocols Nucleospin Extract II kit (Macherey&Nagel). 
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5.1.6 DNA-amplification by PCR 
PCR was used to amplify DNA for preparative and analytical purposes.  
5.1.6.1 Colony PCR for analysis of scFv-antibody clones 
Material from a single bacterial colony from agar plates served as template material. 
Annealing temperature depended on the oligonucleotides used and elongation time 
depended on the size of the amplified fragment (30 s either VH or VL antibody gene, 
60 s complete scFv including VL and VH). Components and PCR-program for a 
typical colony PCR are shown in Tab 1 
Table 1: Components and temperature program for a colony-PCR using pHAL14 vector DNA 
 
5.1.6.2 PCR analysis of scFv-Fc antibody fusions 
Three different vectors were used to  obtain three different scFv-Fc antibodies. 
pCMV2.5-mIgG1Fc-XP, pCMX2.5-hIgG1Fc-XP and pCSE2.5-mIgG2cFc-Xp to obtain 
scFv-mIgG1Fc-, scFv-hIgG1Fc-, scFv-mIgG2cFc antibodies, respectively. Colony-
PCR was performed after transformation of scFv-containing vectors into E. coli XL1-
blue MRF‘ to identify clones containing the correct scFv-Fc antibody gene fragment 
with modifications given in Tab 2. 
Table 2: Oligonucleotides used for the analysis of scFv-Fc antibodies after recloning into 
vectors pCMX2.5-hIgG2cFc-XP, pCMV2.5-mIgG1Fc-XP and pCSE2.5-mIgG2cFc-XP 
 
5.1.7 Restriction digest 
Digests with one or two restriction enzymes per reaction were performed at the 
optimal temperature and buffersaccording to manufacturer‘s protocols. Analytical 
digestions were performed to analyse DNA cleavage products on an agarose or 
polyacrylamide gel; restriction products of preparative restrictions were used for 
cloning procedures. 
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The composition of a restriction digest depended on DNA-concentration and the 
enzyme used. A typical composition of a restriction digest is given in Tab 3. 
Table 3: Typical composition of a restriction digest 
 
Further components like e.g. BSA were added and enzymes were heat inactivated 
after restriction digest where recommended. 
5.1.8 Dephosphorylation of DNA 
Restriction-digested plasmid DNA was dephosphorylated to prevent religation of the 
vector. Therefore, calf intestinal posphatase (CIP, Fermentas, 10 units/µL) was used. 
A total of 0.5 µL were incubated with restricted vector-DNA for 30 min at 37 °C, 
another 0.5 µL CIP were added and incubation time was repeated. 
5.1.9 Ligation of DNA 
T4-DNA-ligase (Promega) was used to ligate linear DNA fragments (inserts) and 
dephosphorylated vector DNA. Ligation was performed at 4-8 °C over night or 1-2 h 
at RT with e ftree-fold excess if insert over vector molecules. A typical ligation 
scheme is shown in Tab 4. 
Table 4: Typical composition of a DNA-ligation 
 
5.1.10 Transformation of DNA into E. coli 
Electroporation was used to transform electrocompetent E. coli XL1-blue MRF‘ 
(Agilent Technologies, Boeblingen, Germany) with plasmid-DNA or ligation samples. 
Up to 10 µL of purified plasmid-DNA or 1.5 µL of ligation sample was supplemented 
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with ice-cold H2O and a maximum of 25 µL electrocompetent XL1-blue MRF‘ to a 
final volume of 50 µL. All mixing steps were perfomed on ice in precooled 
electroporation cuvettes. Electroporation was performed by an electric pulse of      
1.7 kV for ~ 5 ms. 950 µL prewarmed (37 °C) SOC-medium was added immediately 
and the mixture was incubated for 1 h at 37 °C and 600 rpm. Aliquots or dilutions 
thereof were plated on agar-plates (dYT-agar supplemented with 100 mM glucose, 
100 mg/L ampicillin and 20 mg/L tetracycline) and incubated over night at 37 °C to 
obtain single clone colonies of transformants. 
5.1.11 Preparation and purification of phages after pannings 
Single clone colonies grown on agar plates were carefully scraped off the plates in 
dYT-medium supplemented with glucose (100 mM) and ampicillin (100 mg/L). Optical 
density was measured at OD600 and an equivalent of OD600 0.15 was used to 
inoculate 40 mLof the same medium composition. Bacterial culture was incubated at 
37 °C, 250 rpm in shaking flasks until an OD600 of 0.5-0.6 was reached. 10 mL of the 
culture were used for superinfection with a 20fold excess of helperphage M13K07. 
Superinfection was performed for 30 min at 37 °C and 110 rpm in shaking flasks. 
Bacteria were pelleted by centrifugation at 3,220 xg and RT for 10min. Pellet was 
resuspended in 40 mL dYT-medium supplemented with ampicillin (100 mg/L) and 
bacteria were allowed to grow and produce phages over night at 30 °C and 250 rpm. 
Over night cultures were filled in tubes and centrifuged at 10,000 xg and 4°C for 10 
min. A total of 30 mL of the supernatant was transfered to a new tube and mixed with 
7.5 mL 5 x PEG/NaCl by inverting and incubated for 30 min on ice. After an 
additional centrifugation step (10,000 xg and 4°C for 30 min) the phage containing 
pellet was resuspended in 0.8 - 1 mL phage dilution buffer and additionally 
centrifuged at 16,000 xg and 4°C for 10 min. Supernatant was filled into new reaction 
tubes and stored at 4-8 °C.  
5.1.12 Determination of phage titres 
A total of 100 µL of an exponentially growing E. coli XL1-blue MRF‘ culture at OD600 ~ 
0.6 were added to a serial dilution of phage in a microtitre plate, plate was sealed 
with a breathable membrane and incubated for 30 min at 600 rpm in a microtitreplate 
shaker. 5 µL of each dilution were dotted twice and separately onto dYT-agar plates 
supplemented with glucose (100 mM) and ampicillin (100 mg/L). Plates were 
incubated over night at 37 °C and colony forming units were counted.  
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5.1.13 Production of soluble scFv-antibodies in a microtitre plate scale 
To identify specific binders from clones resulting from the panning scFv-antibodies 
were produced in a 96 well microtitre plate (MTP) scale for the use in screening 
ELISA. 
Single clone colonies from agar plates were used to inoculate 100 µL dYT-medium 
supplemented with glucose (100 mM) and ampicillin (100 mg/L) followed by an 
incubation for 6 h at 37 °C and 850 rpm in a MTP-shaker. 15 µL of this pre-culture 
were transfered to a new plate containing 185 µL dYT-medium supplemented with 
glucose (100 mM) and ampicillin (100 mg/L) and incubated for 1 -2 h at 37 °C and 
850 rpm. Bacteria were pelleted by centrifugation at 3,220 xg, RT for 10 min, 
supernatant was discarded and 200 µL dYT-medium supplemented with ampicillin 
(100 mg/L) and 50 µM IPTG were added to allow the production of soluble scFv-
antibodies during an over night incubation at 30 °C and 850 rpm.After over night 
production of soluble scFv antibodies plate was centrifuged at 3,220 xg, 4 °C for 10 
min and supernatant was transfered into a new plate and used for screening ELISA. 
5.1.14 Enzyme linked immunosorbent assay (ELISA) 
To analyse the binding specificity of antibodies of different formats ELISA were 
performed. Target proteins were immobilized to ELISA plates in 50 mM sodium-
carbonate buffer, pH 9.6, over night at 4 - 8 °C. After immobilization supernatant was 
discarded and wells were blocked with 2 % MBPST0.05 % or 2 % BSA PBST0.05 % (300 
µL/well) for 1 h at RT. Wells were washed three times using PBST0.05 %. All antibodies 
were incubated with immobilized target proteins in either 2 % MBPST0.05 % or 2 % 
BSA PBST0.05 % (100 µL/well) for a maximum of 1 h at RT. In screening ELISA 50 µL 
production supernatant of soluble scFv-antibodies were mixed with 2 % MBPST0.05 % 
and incubated on the target protein for 1 h at RT. Wells were washed three times 
with PBST0.05 % after each incubation step. Final incubation step was always 
performed using an HRP-labeled secondary antibody. For staining a mixture of TMB-
A and TMB-B (20:1) was used (100 µL/well) and incubated for 10 min except as 
noted otherwise. Staining reaction was stopped with 1 M H2SO4 (100 µL/well). 
Measurement of optical density was performed at wavelength λ = 450 nm with 
reference at OD600 using an MTP reader. 
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5.1.15 SDS-PAGE 
Proteins were separated using a 12 % SDS-containing polyacrylamide gel (Tab 5.). 5 
x Laemmli-buffer (including -mercaptoethanol for reducing conditions, without -
mercaptoethanol for non-reducing conditions) was added to protein samples that 
were heated for 8 min at 94 °C (reducing) or 56 °C (non-reducing). Proteins were 
separated at 25 mA, 300 V for 45 – 50 min. 
Table 5: Composition of a 12 % separation and a 4 % stacking gel for SDS-polyacrylamide gel 
 
5.1.16 Coomassie staining of protein gels 
After SDS-PAGE protein gels were transfered into a beaker, covered with 
Coomassie-staining solution, boiled using a microwave and incubated for 5 min. 
Staining solution was removed followed by 2 -3 washing steps using H2O and heating 
using the microwave. Stained gels were stored in H2O. 
5.1.17 Silver staining of protein gels 
Silver staining of protein gels were performed using silver stainig kit (GE Healthcare) 
according to manufacturer‘s procedure. 
5.1.18 Immunoblots 
Proteins separated on an SDS-gel were blotted onto a PVDF-membrane using a 
semidry-blotting procedure. PVDF-membrane was incubated for 2 -3 min in 
methanol. Blotting of proteins onto the membrane was performed at 0.45 mA/cm2 gel, 
300 W, 20 V for 25 min. After blotting the membrane was blocked for 10 min in 2 % 
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Tween PBS. The blocked membrane was washed three times in PBS, 5 min each. 
Target protein specific antibodies were incubated in MPBST0.05 with the membrane 
for 1 h at RT. Secondary antibody was either HRP- or AP labeled and incubated in 
MPBST0.05 for 1 h at RT. Each incubation step was followed by three washing steps 
using PBST0.05 %, 5 mineach. Staining of AP-labeled secondary antibodies was 
performed using AP-substrate buffer and NBT/BCIP (each 1:100 in substrate buffer). 
For staining of HRP-labeled secondary antibodies DAB with its respective substrate 
buffer and 37 % H2O2 (1:10,000). Staining reactions were stopped with H2O. 
Commercial antibodies used for immunoblot and their appropriate dilution for this 
application are summarized in section 3.10. 
5.1.19 Hemagglutination inhibition test (HI) 
Using a hemagglutination test (HA test) viruses can be detected that are able to 
agglutinate erythrocytes via virus surface proteins. In this assay virus amount is 
defined as hemagglutination units that are calculated in log 2.  
In a hemagglutination inhibition test (HI) antibodies can be analysed with regard to 
their ability to inhibit hemagglutination due to binding to hemagglutinin and thereby 
masking sites necessary for the agglutination of erythrocytes. HI-positive antibodies 
have a high potential to serve as neutralizing antibodies. 
Chicken blood was supplemented with sodium citrate or heparin to prevent 
agglutination. Erythrocytes were washed in PBS three times and centrifuged at 1500 
rpm for 10 min at 4 °C after each washing step. From the sediment a 1 % (v/v) 
chicken erythrocyte solution was prepared und used for this assay. For positive 
control the following antigen was used: Newcastle Disease Virus (NDV) Ulster  (4th 
egg passage, 11.9.2007, inactivated antigen, K-number 3709; FLI) that gives a 
hemagglutination titre of 8 (+/-1 log2 step). The assay was performed in round-bottom 
MTP plates. 
For the HI test first of all the virus amount needs to be fixed to 4 hemagglutination 
units (HAU 4, dilution 1:16) for all viruses to be assayed. A total amount of 25 µL 
NaCl 0.85 % (w/v) per well was mixed with an equal amount of virus containing 
solution and eleven similar serial dilutions were performed (dilutions 1:2 to 1:4096). A 
total of 25 µL of a 1 % chicken erythrocytes solution is added per well and incubated 
for 30 min at RT. The last virus dilution with positive hemagglutination (slow 
sedimentation compared to erythrocyte control, formation of a ―cobweb‖-like 
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structure) is used to calculate HAU 4. Accuracy of HAU 4 determination was 
controlled by a control HA test. Each HA test required a positive control (NDV Ulster 
titration) and a negative control (erythrocytes without virus). 
Serial antibody dilutions of 1:2 with virus dilution at HAU 4 were incubated for 1 h at 
RT. After the additon of 25 µL of a 1 % chicken erythrocyte solution and an additional 
incubation for 30 min at RT the hemagglutination inhibition concentration of the 
assayed antibody can be calculated from the last well were agglutination is inhibited 
(no hemagglutination detectable).Each HI test required a positive control (virus with 
antibody) and two negative controls (erythrocytes without virus and antibody as well 
as erythrocytes with antibody dilutions). 
5.1.20 Immunoperoxidase assay (IPMA) 
Two different cell lines were used for this cell based ELISA. Cell lines and viruses as 
were provided by the FLI.  
A swine testis cell line (STOMA24) was used for the infection with low pathogenic 
influenza viruses presenting viral proteins – among them hemagglutinin on their 
surface upon infection. To present hemagglutinins of highly pathogenic influenza 
viruses on the cell surface recombinant insect cells (High Five) constantly expressing 
the respective hemagglutinin were used. 
The amount of virus to be used had to be titrated first to guarantee an infection of 5 -
15 % of the cells per well. From a confluent cell culture of adherent swine testis cells 
in a middle-size cell culture flask medium was removed, wells were washed using 2 – 
3 mL trypsin containing solution (―ATV-D‖, FLI) and detached using 5 mL ATV-D and 
an incubation period of 5 min at 37 °C. Serum free medium (―5ZB-D‖, FLI) 
supplemented with G418 EK [400µg/mL], Hygromycin EK [200µg/mL] and 
Doxycycline [300ng/mL] was used to give a total volume of 40 mL. A total volume of 
100 µL cell suspension was added to 100 µL of the respective virus solution per well 
and virus replication was allowed for 2 days at 37 °C and 5 % CO2.  
After infection medium was removed and cells were washed using 100 µL PBS per 
well. Fixation of the cells was performed using 100 µL fixation solution (40 % 
methanol, 60 % acetone) per well during an incubation of 5 min. Fixation solution 
was removed and cells were carefully air-dried. Fixed cells were incubated for 30 min 
at RT with 50 µL TBST per well supplemented with 0.03 % (v/v) H2O2. After removing 
the supernatant cells were washed in TBST followed by the incubation of the first 
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antibody (500 ng scFv-hIgG1Fc antibody in 50 µL TBSTper well; 1 h, RT). After three 
washing steps (each 250 µL TBST) wells were incubated with a secondary HRP-
conjugated goat-anti-humanFc antibody (1:500 dilution in TBST) for 1 h at RT. After 
three washing steps (each 50 µL TBST) wells were incubated for 15-30 min at RT in 
50 µL staining solution (0.05 M sodium acetate pH 5.0 containing 0.03 % (v/v) H2O2 
and 5 % (v/v) ACE-stock solution) per well. Staining solution was removed and wells 
were washed using 50 µL H2O per well. Per antibody and virus four independent 
wells were analysed. 
5.1.21 Virus Neutralization assay (VN) 
MDCK+ cells were used for virus neutralization and assays were performed in 96 well 
MTP plates in serum free medium (―5ZB-D‖, FLI). Cells, medium and all supplements 
were provided by the FLI. MDCK+ cells were prepared to be seeded in 96 well MTP 
plates according to the following procedure:  
From a 150 cm2 flaskof confluent MDCK+ cells medium was removed and cells were 
washed in 5 mL ATV-D (trypsin containing solution). Supernatant was removed and 
cells were incubated in 5 mL ATV-D at 37 °C, 5 % CO2 for no longer than 50 min until 
cells were detached. Cell suspension was transfered to a 15 mL tube supplemented 
with 2 mL (―ZB 5b 5% FCS‖, FLI) and centrifuged at 800 rpm and RT for 2 min. 
Supernatant was removed, 5x104 – 1x105 cells per well were seeded in serum 
containing medium and incubated for one day at 37 °C, 5 % CO2. 
For all viruses to be used 100 TCID50 (100 fold the amount of virus needed to infect 
50 % of all cells) had to be determined since this virus amount was used for virus 
neutralization assays. Virus amount had to be confirmed via backtitration at the day 
when VN assay was performed. 
Log 2 serial antibody dilutions were performed in serum free medium (―5ZB-D‖, FLI) 
and 50 µL of each dilution step was preincubated with 50 µL virus suspension at 
100TCID50 for 1 h at RT. Cells in 96 well plates were washed with 100 µL serum free 
medium (―5ZB-D‖, FLI). 50 µL of serum free medium supplemented with trypsin 
(TPCK, FLI) at a final concentration of 2 µg/mL was added together with the 100 µL 
preincubated antibody/virus mixture. Plates were incubated for 72 h at 37 °C and 5 % 
CO2 before wells were analysed using a microscope. Four separate wells were 
analysed per antibody concentration and virus. Antibody was regarded to be 
neutralizing when no cytopathic effect could be observed in all four wells. 
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Due to unexpected negative VN-results for antibody JM7_8 and to reduce potential 
negative effects of trypsin on antibody stability described standard procedure was 
altered according to the following protocol: 
After cells were washed antibody/virus mixture was added to the cells and infection 
of the cells was allowed for 6 h at 37 °C and 5 % CO2. Only then trypsin containing 
medium was added and plates were incubated for 66 h at 37 °C and 5 % CO2. 
5.2 Immunization of chickens 
Specific Pathogen-Free (SPF) chickens were immunized at the age of three weeks 
with a vaccine based on the virus isolate A/duck/Anhui/2006 (Chinese commercial 
inactivated vaccine Re-5). Three weeks later these birds were infected with 
A/chicken/Egypt/0879 - NLQP/2008 H5N1 virus (106 TCID50/bird). All immunized 
birds survived without developing clinical symptoms until day 14 after second 
immunization120. The birds were then sacrificed and heparinised blood samples and 
spleens were obtained for isolation of lymphocytes. All experimental procedures 
followed official German animal welfare regulations (permission LALLF 127M-
V/TSD/7221.3-2.1-031/09) and were perfomed byDr. Christian Grund at the FLI. 
5.3 Purification of influenza viruses 
Virus A/teal/Föhr/Wv632/05 (H5N1, LP) was propagated in 9 to 11 days old  SPF 
embryonated chicken eggs and inactivated using beta-propriolactone according to an 
OIE protocol. Allantoic fluid containing the virus was harvested after decapping the 
egg and centrifuged at 3500 rpm for 30 min. Clear supernatant was loaded onto a 
sucrose gradient (60%, 35% (w/v) with 5mL of each sucrose fraction; sucrose 
dissolved in Tris-buffer (100 mM Tris pH7.4, 3mM EDTA pH7.2) and centrifuged for 2 
hours at 27,000 rpm and 4°C using a Beckmann LE-70 ultracentrifuge (rotor SW32) 
with ultraclear centrifuge tubes (38.5 mL, SW28/32). Virus containing band was 
diluted 1:2 in Tris buffer and loaded onto a second sucrose gradient (60/50/40/30% 
(w/v) sucrose; 7 mL each fraction) and centrifuged over night at 27,000 rpm, 4°C. 
White, virus containing band was diluted 1:5 in 0.85% (w/v) NaCl and pelleted at 
27,000 rpm, 4°C for 90 min. Virus pellet was finally resuspended in 0.85% NaCl. 
5.4 Generation of chicken immune libraries 
Two different anti-H5 chicken immune antibody-libraries were constructed i) from 
spleen (referred to as KFC_AIV2_S) and ii) from peripheral blood lymphocytes 
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(referred to as KFC_AIV2_B). 
5.4.1 Isolation of RNA 
Isolation of RNA was performed by the FLI using Qiagen RNeasy RNA-isolation kit 
according to FLI standard protocols. 
Isolated RNA was shipped at 4 – 8 °C and further used at the day of delivery. 
5.4.2 Reverse transcription 
RNA was reverse transcribed using Superscript-II (Invitrogen, Darmstadt, Germany) 
and random hexamer oligonucleotides (denaturation 70°C for 5 min, synthesis 10 
min 25°C, 50 min 42°C and finally 15 min 70°C). 
5.4.3 cDNA-synthesis 
The RNA content was measured and RNA amount used for cDNA synthesis was 
calculated (values not shown). Mix I (consisting of random oligonucleotides and 
dNTP-mix) was added to RNA, mix was incubated at 70 °C for 5 min to denature 
RNA followed by a 5 min incubation step on ice. Mix II (consisting of 5xFS-buffer and 
DTT) was added afterwards and 1 µL Superskript II Reverse Transkriptase (200 
U/µL)per sample was added separately. A three step synthesis program was 
performed (10 min at 25 °C, 50 min at 42 °C, 15 min at 70 °C). Storage of cDNA was 
avoided and immediately processed for amplification of chicken antibody genes via 
PCR. 
Table 6: Composition and procedure for cDNA synthesis from total RNA isolated from 
chicken blood (B) and spleen (S) to construct anti-H5 chicken immune antibody 
libraries KFC_AIV2_S and KFC_AIV2_B 
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5.4.4 Amplification of chicken antibody genes – first PCR 
Chicken specific IgG-oligonucleotides were used to amplify variable (V) heavy (H) 
and light (L) chains in a first PCR using oligonucleotides shown in section 4.8. A total 
of 26 PCR samples for 9 cDNA_samples from peripheral blood lymphocytes (9 
individual chickens) and 4 cDNA-samples from spleen-RNA (4 individual chickens) 
were performed. 
Table 7: Pipetting scheme for PCR to amplify antibody gene fragments from cDNA to 
construct chicken immune antibody libraries 
 
A total of 28µL of the respective oligonucleotide for the amplification of chicken VH 
and VL antibody chains (10 µM) was added to the PCR mixture. Both VL- and VH-
PCR-mixes were aliquoted in PCR tubes. 48.6 µL per tube and 1.6µL of the 
respective cDNA was added to each tube. Thus two samples (VH and VL) were 
obtained for each amplified cDNA. The following PCR-program was run: 3 min 94°C, 
30 s 94°C / 30 s 60°C / 30 s 70°C / 10 min 72°C. A total of 25 cycles was performed. 
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PCR samples were separated on a 1.5 % agarose gel via gel-electrophoresis. Gel 
was run for 40 min at 100V. DNA bands of correct size (VL 350bp, VH 390bp) were 
excised and purifiedusing MNNucleospin Kit for each PCR sample separately 
according to manufacturer‘s procedure. Final volume for elution was 35 µL for each 
sample. 
5.4.5 Introduction of restiction sites – second PCR 
Restriction cloning sites (NcoI/HindIII for VH and MluI/NotI for VL) were inserted by a 
second PCR. Used oligonucleotides are listed in section 4.8. 
A total of 1µL of the appropriate 10 µM oligonucleotide stock (VH: MHChickVH_f and 
MHChickVH_r2; VL: MHChickVL_MLuI_f and MHChickVL_NotI_r) was used per 
reaction. A total of 30 ng PCR-product from first PCR was used for samles obtained 
from blood and 50 ng for those obtained from spleen. Final volume of each PCR-
reaction was 50 µL. 
A total of 25 PCR cycles were run in a two step-PCR. First 10 cycles were run with 
lower annealing temperature - 3 min 94 °C, 30 s 94 °C / 30 s 60 °C for VH and 55 °C 
for VL, 30 s 70°C; the following 15 cycles were run at higher annealing temperature: 
3 min 94 °C, 30 s 94 °C / 30 s 67 °C for VH and and VL, 30 s 70 °C followed by a    
10 min 72 °C step. 
PCR samples were separated on a 1.5 % agarose gel via gel-electrophoresis for 40 
min at 100V. DNA bands of correct size (VL 350bp, VH 390bp) were excised and 
purifiedusing MNNucleospin Kit for each PCR sample separately according to 
manufacturer‘s procedure. Final volume for elution was 37 µL for each sample. 
5.4.6 Restriction digest and ligation of antibody gene fragments and pHAL 14 vector 
Amplified chicken antibody gene fragments were digested using appropriate 
restriction enzymes (VL – HindIII/NcoI and VH – MluI/NotI, according to Tab 8). A 
total of 5 µg pHAL14 vector and 1 µg insert VL and VH were digested. VH and VL 
samples of blood and spleen origin were pooled to give pools of VH- and VL – PCR 
fragments of blood and splenic origin each. In this work VH - antibody gene 
fragments were cloned first into pHAL 14 phage display vector. Restriction digests 
were performed as shown in Tab 8 and fragments were cloned into pHAL 14 vector 
according to ligation shown in Tab 9 using 1 µg vector DNA and 250 ng insert DNA 
over night at 4-8 °C and inactivated for 10 min at 65 °C. Following inactivation DNA 
was precipitated  and transformed. 
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Table 8: Restriction digest of VH antibody gene fragments from blood (B) or splenic (S) origin 
and pHAL 14 antibody phage vector 
 
 
Table 9: Ligation of VH antibody gene fragments from blood (B) or splenic (S) origin into pHAL 
14 phage display vector 
 
 
Table 10: Restriction digest scheme of VH-pHAL14 and VL antibody gene fragments prior 
cloning VL fragments into VH-pHAL14 phage display vector 
  Methods 
  58  
 
Ligation of VL antibody fragments and pHAL 14 vector containg VH antibody gene 
fragments was performed as shown in Tab with 250 ng insert (VL) and 1 µg vector 
DNA.Following inactivation of the ligation (10 min, 65 °C) DNA was precipitated and 
transformed via electroporation in E. coli XL1-Blue MRF‘ (Agilent) with three shots 
each 10 µL DNA, pHAL 14 vector DNA including complete scFv chicken antibody 
gene fragments was produced in E. coli XL1-Blue MRF‘ and purified. 
 
5.4.7 Packaging of chicken antibody genes into phage libraries 
To obtain phage libraries in which chicken scFv-antibodies are fused to the pIII-
phage coat protein and thus presented on the surface of the phage single clone 
colonies were scraped off agar plates using dYT-medium supplemented with 100 mM 
glucose and ampicillin (100 mg/L). Optical density was measured at OD600 and an 
equivalent of OD 0.15 was used to inoculate two cultures of each 400 mLof the same 
medium composition. Bacterial culture was incubated at 37 °C, 250 rpm in 2 L 
shaking flasks until OD600 of 0.5 was reached. Two cultures of 40 mL were used for 
superinfection with a 20fold excess of helperphage M13K07 supernatant. 
Superinfection was allowed for 30 min at 37 °C and 110 rpm in 500 mL shaking 
flasks. Culture was filled in 50 mL tubes and bacteria were pelleted by centrifugation 
at 3,220 xg and RT for 10min. Pellet was resuspended in 400 mL dYT-medium 
supplemented with ampicillin (100 mg/L) and bacteria were allowed to grow and 
  Methods 
  59  
produce phages over night at 30 °C and 250 rpm in 2 L shaking flasks. Remaining 
culture volume from 400 mL pre-culture was aliquoted each 45 mL in 50 mL tubes 
and centrifuged at 3,220 xg for 10 min at RT. Supernatant was discarded and pellet 
was resuspended in 500 µL dYT-medium supplemented with ampicillin (100 mg/L) 
and 250 µL 80% glycerol(v/v). The mixture was frozen in twist-off caps in liquid 
nitrogen to be stored at - 80 °C. 
5.4.8 Purification of chicken immune library antibody phages 
Purification of chicken immune library antibody phages was performed with 
modifications. After centrifugation of over night cultures, 200 mL of the supernatant 
were transfered into a new SLA 3000 tube and mixed with 50 mL 5 x PEG/NaCl by 
inverting and incubated for 30min on ice. After an additional centrifugation step 
(10,000 xg and 4°C for 30 min) pellet was resuspended in 10 mL phage dilution 
buffer, and additionally centrifuged at 20,000 xg and 4°C for 10 min. To the 
supernatant 5 mL 5 x PEG/NaCl were added, mixed and incubated for 1 h on ice. 
Supernatant was cleared by an additional centrifugation step (30 min, 4 °C, 20,000 
xg) and each pellet was resuspended in 1mL phage dilution buffer. After the last 
centrifugation step (16,000 xg, 4°C, 10 min) supernatant was stored at 4 – 8 °C. 
5.5 Immobilization of H5 
For the immobilization of the two different recombinant H5 antigens four different 
surfaces were used resulting in five different immobilization procedures. A short 
overview on H5 immobilization procedures is given in Fig 14. 
5.5.1 Immobilization of human H5 to carboxylic beads 
Recombinant human H5 A/Anhui/1/2005 protein was immobilized to Dynabeads® 
M270 carboxylic beads according to manufacturer‘s procedures. A total of 10 μL 
beads was activated using a mixture of 100 µL 0.1 M N-hydroxysuccinimide (NHS) 
and 100µL 0.5 M 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) 
bya 8 min incubation at RT. After two short wash steps with 10 mM sodium acetate 
buffer, pH 5.0, 500 ng of recombinant H5 were immobilized in 10 mM sodium acetate 
buffer, pH 5.0 for 20 min at RT in a final volume of 120 μL. Subsequently, beads 
were washed with PBS and blocked with 50mM ethanolamine for 1h at RT. Finally 
beads were washed with PBST (PBS containing 0.05% (v/v) Tween-20) and blocked 
with 1 % BSA PBST for 1h at RT. 
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5.5.2 Immobilization of human H5 to epoxylic beads 
Recombinant human H5 A/Anhui/1/2005 protein was immobilized epoxylic magnetic 
beads using two different coupling buffers: PBS, pH 7.4 or 100 mM sodium borate, 
pH 8.6. Immobilization was performed at 6 °C in a thermomixer, shaking at 800 rpm 
using a 2 mL round bottom reaction tube. Following incubation beads were washed 
twice with the respective coupling buffer and bead surface was saturated using 50 
mM ethanolamine in PBS (1 mL per reaction tube) for 1 h at RT, rotation. Following 
saturation beads were washed twice using PBST and blocked with blocking buffer (2 
% MPBST or 2 % BSA PBST) for 1 h at RT, rotating. 
5.5.3 Immobilization of human H5 to ELISA plates 
Recombinant human H5 A/Anhui/1/2005 protein was immobilized to ELISA plates in 
50 mM sodium carbonate buffer pH 9.6 over night at 4-8 °C. For ELISA using scFv-
Fc antibodies 50-75 ng/ well were immobilized. Following immobilization wells were 
blocked with blocking buffer (2 % MPBST or 2 % BSA PBST) for 1 h at RT, 300 
µL/well. 
5.5.4 Immobilization of avian H5 to streptavidin beads 
Biotinylated recombinant trimeric avian H5A/Canada goose/Germany/71/06protein 
was immobilized to Dynabeads® M280 Streptavidin (Invitrogen, Darmstadt, 
Germany) according to manufacturer‘s procedures. Briefly, 10 μL streptavidin beads 
were incubated with in 200 μL baculovirus-expression supernatant for 1h at RT and 
then blocked with PBST supplemented with 1% (w/v) skim milk for 1h at RT. 
5.6 Pannings 
In general: 
A total of two to three successive rounds of panning were performed. First panning 
round: A total of 5x1011 cfu (colony forming units) of each antibody phage library was 
incubated on immobilized H5 target for 60 - 80 min at RT in 1% BSA PBST. Beads 
were washed 15 times with 800 μL PBST. Bound phages were eluted from beads by 
incubation with 200 μL 10 μg/mL trypsin for 30 min at 37°C shaking at 600 rpm. A 
total of 5 mL E. coliXL1-blue MRF‘ were inoculated in dYT medium supplemented 
with 20 µg/mL tetracycline at 250 rpm at 37°C were infected at an OD600= 0.5 – 0.6 
with the eluted phage by incubation for 30 min at 37°C and shaking at 110 rpm. Cells 
were plated onto dYT-agar plates supplemented with 100 mM glucose, 100 μg/mL 
ampicillin and 20 µg/mL tetracycline (dYT-GAT). Plates were incubated over night at 
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37°C. For the following two panning rounds 1 % MPBST and 1% BSA PBST was 
used for blocking, respectively and 25 or 20 washings steps were performed 
respectively. 
5.6.1 Pannings using human naïve antibody libraries 
5.6.1.1 Pannings on human H5 target immobilized to ELISA plates 
Human recombinant H5 A/Anhui/1/2005 target was immobilized as described in 
section 4.5.3. Pannings were performed using naïve human antibody libraries HAL7 
and HAL4 (hyperphage packaged). 
First round of panning: A total of 250 ng H5 protein was immobilized per well and 4 
wells were used. A total of 5x1011cfu phages were used per library, phage were 
pooled and first preincubated for 15 min in 1 % BSA PBST. Second preincubation 
step was performed in 1 % BSA PBST blocked ELISA plate wells (300 µL 2 % BSA 
PBST per well for immobilization 1 h, RT) using 100 µL preincubated phage per well. 
After incubation of phage on the target for 90 min at RT shaking, wells were washed 
10 x PBST (bottom-wash program using Columbus ELISA washer) and elution of 
phage were performed using 100 µL 10 µg/mL trypsine per well for 30 min at 37 °C 
and 800 rpm in a MTP shaker. Second round of panning: A total of 500 ng H5 protein 
was immobilized per well and 2 wells were used. A total of 7.6x1011cfu phages from 
first panning round with 1 % MBST used as blocking buffer. After incubation of phage 
on the target for 60 min at RT shaking wells were washed 30 x PBST. Third round of 
panning: was performed similar to the second round with 4x109 cfu phages from 
second panning round and 1 % BSA PBST used as blocking buffer. After incubation 
of phage on the target for 90 min at RT shaking wells were washed 20 x PBST  
5.6.1.2 Pannings on human H5 target immobilized to magnetic beads 
Human recombinant H5 A/Anhui/1/2005 target was immobilized as described in 
section 4.5.1 and 4.5.2. Pannings were performed using naïve human antibody 
libraries HAL7 and HAL4 (hyperphage packaged). 
First round of panning: A total of 500 ng H5 protein was immobilized to carboxylic 
and epoxylic magnetic beads, 10 µL each. A total of 5x1011cfu phages were used per 
library, phage were pooled and first preincubated in 800 µL 1 % BSA PBST for 15 
min, at RT, rotating. Blocked target beads were incubated with preincubated phage 
for 1 h at RT, rotating. Beads were washed 15 times with each 800 µL PBST within 
30 min. Elution and phage recovery was performed as described under 5.6 – in 
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general. Second round of panning: A total of 250 ng H5 protein was used and 8x1010 
cfu phages from first panning with 1 % MPBST as blocking buffer. Beads were 
washed 20 times. Third round of panning: was performed similar to procedure for the 
second panning round. Incubation and blocking buffer was 1% BSA PBST and phage 
input was ~ 5 x 109 cfu. 
5.6.2 Pannings using chicken immune libraries 
Two different H5 antigens were used for these series of pannings. Recombinant 
human H5 A/Anhui/1/2005 was immobilized to carboxylic beads and recombinant 
avian H5 antigen A/Canada goose/Germany/71/06 to streptavidin beads. A summary 
of the panning procedure is given in Fig 12. 
 
Figure 12: Scheme of panning campaigns to identify anti-H5 chicken antibodies 
5.6.2.1 Panning on recombinant human H5 
A total of two successive rounds of panning was performed. First panning round: A 
total of 5x1011 cfu of each phage immune library KFC2_AIV_S and KFC2_AIV_B was 
incubated separately on H5 beads for 80 min at RT in 1% BSA PBST. Afterwards, 
beads were washed 15 times with 800 μL PBST. Second panning round:Amplified 
phage preparations from first panning round (KFC-AIV2-S: 1x1011 cfu, KFC_AIV2_B: 
5x1010 cfu) were incubated with H5 antigen coated beads in 1 % MPBST. Beads 
were washed 25 times. After two panning rounds single clones were isolated.  
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5.6.2.2 Panning on recombinant avian H5 
Panning procedure was similar to procedure described in 4.6.2.1 with modifications. 
Streptavidin beads were coated with 200 µL biotinylated avian trimeric H5 A/Canada 
goose/Germany/71/05 from cell culture supernatant for 60 min at RT. Beads were 
washed with PBST and blocked in 2 % MPBST in the first panning round or in 2 % 
BSA PBS in the second round of panning. The immune libraries were diluted in 
blocking buffer and incubated with blocked andH5 antigen coated beads, 1 h at RT, 
rotating for each incubation step. A total of 15 or 25 washing steps was performed in 
the first or second panning round, respectively. 
5.7 Screening for scFv antibodies via ELISA 
In general: For screening ELISA scFv antibodies were produced in microtitre plates. 
H5 target antigens were immobilized to various surfaces as described in section 4.5. 
A total of 50 µL of scFv antibody production supernatant was incubated on 
immobilized target in blocking buffer (either 1 % MPBST or 1 % BSA PBST) to a final 
amount of 100 µL per well for 1 h at RT. For bead immobilized target 1 µL beads was 
used per well. Following this washing step wells were incubated with 100 µL mouse-
anti-c-myc antibody in a final concentration of 1:1000 – 1:2000 depending on the 
antibody preparation (in house production) using blocking buffer for 1 h at RT. An 
HRP-conjugated goat-anti-mouse Fc antibody 1:1000 diluted in blocking buffer was 
used for secondary antibody. Each antibody incubation was followed by a washing 
step in PBST (three times) using either Tecan Columbus pro washer (for MTP 
immobilized target) or Tecan hydroflex bead washer (for bead immobilized target). 
Staining was performed using TMB (TMB A/TMB B 20:1, 100 µL per well) for 10 min, 
reaction was stopped by addition of 100 µL 1 N H2SO4. OD450 nm measurements were 
performed at (reference at 600 nm) using a 96 well-plate reader. 
5.8 Cloning of scFv-antibody genes into scFv-Fc-antibody format 
Three different scFv-Fc expression vectors were used – pCMX2.5-hIgG1Fc-XP, 
pCMV2.5-mIgG1Fc-XP and pCSE2.5-mIgG2cFc-XP to express different scFv-Fc 
antibodies scFv-humanIgG1Fc, scFv-mouseIgG1Fc and scFv-mouseIgG2cFc, 
respectively. 
ScFv-antibody fragment was isolated from pHAL14 vector using restriction enzymes 
NcoI and NotI. Restriction digest was loaded onto a 1 % agarose gel, scFv-DNA 
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insert was separated from vector background by gel electrophoresis and scFv-DNA 
insert, ~ 900 bp in size, was excised from gel and purified using Macherey&Nagel 
Nucleospin Gel and PCR clean up kit (MN DNA purification kit). ScFv-Fc expression 
vectors were treated with restriction enzymes NcoI and NotI, purified by MN DNA 
purification kit using a modified procedure according to manufacturer‘s 
recommendation and dephosphorylated. ScFv-DNA insert and dephosphorylated 
vector were ligated ( ~ 40 ng of vector DNA and ~ 40 ng of insert DNA), inactivated 
and transformed into E. coli XL1-blue MRF‘. Following an incubation over night at   
37 °C single cones were used to perform colony PCR to identify clones having 
incorporated the respective scFv-Fc expression vector including an scFv-fragment. 
Bacteria containing the insert of correct size were used to amplify plasmid DNA and 
plasmid DNA was purified using MN Nucleobond Xtra Midi Kit according 
manufacturer‘s protocols. Precipitated DNA was eluted in H2O and used for 
transfection of HEK cells.  
5.9 Production of scFv-Fc antibodies 
ScFv-Fc antibodies were produced in mammalian cells – either adherent HEK293T 
or in HEK293-6E in shaking. 
5.9.1 Expression of scFv-Fc antibodies in HEK293T cells 
Confluent HEK293T plates were split 1:4 using DMEM medium supplemented with   
8 % (v/v) FCS and 1 % penicillin/streptomycin 13 mL per plate. 10 µg DNA was 
mixed with 400 µL DMEM medium in one well of a 12 well plate and 400 µL DMEM 
was mixed with 80 µL PEI [1 mg/ mL]] in a second well. Content of both wells were 
mixed and incubated for 20 -30 min at RT. Transformation mixture added to the cells 
and plates were incubated at 37 °C and 7 % CO2. After 24 h medium was removed 
and DMEM supplemented with 4 % (v/v) low IgG FCS and 1 % 
penicillin/streptomycin was added. Culture supernatant was harvested every day and 
fresh medium was added. Production of scFv-Fc antibodies was continued for up to 
10 days, harvested culture supernatant was stored at 4 - 8 °C. 
5.9.2 Expression of scFv-Fc antibodies in HEK293-6E cells 
ScFv-Fc antibodies were produced in shaking culture using HEK293-6E cells. 
Optimal cell number is 1.7 -2 million cells per mL, culture medium is FreeStyle F17 
expression medium (GIBCO) supplemented with 7.5 mM glutamine and 0.1 % (w/v) 
pluronic F68. Transfection procedure is described for a 100 mL standard production 
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scale. 100 µg DNA was mixed with 3 mL medium in one well and 3 mL medium was 
mixed with 250 µL PEI [1 mg/ mL] in a second well. Content of both wells were mixed 
by slowly pipetting up and down and incubated for 20 -30 min at RT. Transfection 
mixture was added to shaking cell culture and cells were incubated at 37 °C, 5% CO2 
and 111 rpm. Two days after transfection 50 mL medium F17 complete containing 
0,5% (w/v) TN1-tryptonewas added. Production of scFv-Fc antibodies was allowed 
for up to six days. 
5.10 Purification of scFv-Fc antibodies 
ScFv-Fc antibodies were purified using Profinia™ (BIO-RAD) protein A affinity gel 
chromatography columns. Cell culture supernatants were centrifuged at 2000 rpm for 
10 min. Prolonged storage of cell culture supernatants was avoided but if necessary 
0.5 % (v/v) low IgG FCS wasadded to reduce degradation of scFv-Fc antibodies by 
proteases. Cell free supernatants were harvested and 1/10 volume of 10 x Profinia 
protein A binding buffer was added, supernatant was filtered using an 0.45 nm filter 
membrane and used for protein A gel chomatography. ScFv-hIgG1Fc and scFv-
mIgG2cFc antibodies were purified using standard BIO-RAD protocol for Profinia 
Protein A purification. 
ScFv-mIgG1Fc antibodies were purified under high salt conditions adding NaCl to 
final 2 M to the cell culture supernatant and using a 1 x high salt binding buffer (2 M 
NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4,  8.1 mM KH2PO4). 
5.11 Epitope mapping 
Epitope mapping was performed on a cellulose acetate membrane onto which 15 
amino acids long peptides with a three amino acid overlap were immobilized 
representing the complete amino acid sequence of the target protein human H5 
A/Anhui/1/05 provided by Dr. Ronald Frank, HZI. Membrane was blocked in 2 % 
MPBST for 1 h at RT. A minimal amount of 10 µg scFv-mIgG1Fc antibodies 
wasincubated with the membrane in a maximum of 10 mL 2 % MPBST for 2.5 h at 
RT. After two washing steps in PBS for 5 min each the secondary antibody goat-α-
Mouse IgG (Fc-specific) AP in a final dilution of 1:2,000 was incubated with the 
membrane in 10 mL 2 % MPBST for 1.5 h at RT. The membrane was washed twice 
5 min each with TBST 0.05 % and twice 10 min each with CBS. Detection was 
performed using 10 mL staining solution consisting of CBS supplemented with 50 µL 
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1 M MgCl2, 40 µL BCIP and 60 mL MTT (5 mg/mL). Incubation was performed over 
night protected from light. Membrane was washed twice with PBS before scanning. 
Membrane was stripped to remove staining and bound antibodies according to the 
following procedure with each washing step performed for 5 -10 min: 3 x H2O, 2 x 
DMF, 3 x Stripping buffer A, 3 x Stripping buffer B, 3 x 100 % ethanol. After stripping 
membrane was stored at -20 °C. 
5.12 Protein structure modelling 
Hemagglutinin H5 protein sequence was derived from RCBS protein database (PDB 
accession number 2FK0186 and protein structure was modelled using iMol. 
5.13 Transmission electron microscopy 
Sample preparatation and transmission electron microscopy was carried out by Prof. 
Dr. Manfred Rohde at the Helmholtz Center for Infection (HZI), Braunschweig. Thin 
carbon support films, approximately 10 nm thick, were prepared by sublimation of 
carbon from a carbon thread on to freshly cleaved mica strip. Using 300 mesh nickel 
grids virus samples were negatively stained with 4% (w/v) aqueous uranyl acetate187. 
Antibodies were directly labeled with 15 nm protein-A-gold according to 
manufacturer‘s procedures. Antibody labeled virus samples were stained by placing 
a butvar-coated 300 mesh copper grid for 30 sec on a drop of the virus suspension, 
washed in TE buffer and then negatively stained with a 2 % (w/v) aqueous uranyl 
acetate solution. Negatively stained samples were examined in a TEM with an 
acceleration voltage of 80 kV and at calibrated magnifications. Images were recorded 
digitally with a camera and respective software. For field emission scanning electron 
microscopy samples were adsorbed on to butvar-coated 300 mesh copper grids by 
placing a grid for 30 sec on a drop of the antibody labelled virus suspension, washed 
in TE-buffer, washed in H2O and subsequentely air-dried. Grids were mounted on to 
conductive adhesive tabs on aluminum stubs. Samples were examined in a field 
emission scanning electron microscope using the Everhart-Thornley SE-detector and 
the inlens SE-detector in a 75:25 ratio at an acceleration voltage of 3 kV. 
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6 Results 
6.1 Isolation of human anti H5 specific antibodies 
6.1.1 Immobilization of recombinant human H5 
To check for optimal immobilization conditions of recombinant human H5 
A/Anhui/1/2005 target,  various surfaces were used for initial immoblilization assays. 
Since conformational stability of the H5 molecule concerning pH value and 
temperature was yet unknown, different conditions were tested before pannings. 
Three different immobilization strategies were analysed: ELISA plates and magnetic 
beads with either carboxylic acid groups or epoxylic acid groups on their surface    
(Fig 13). Best immobilization conditions were obtained for immobilization to 
carboxylic beads using NHS/EDC coupling and 10 mM sodium acetate buffer pH5.0 
with complete coupling of the target, indicated by the loss of protein band after 
coupling. Immobilization efficiency to ELISA plates and Epoxy beads – irrespective of 
immobilization buffer – was comparable but less efficient for all three coupling 
procedures compared to immobilization to carboxylic bead. 
 
Figure 13: Immobilization of recombinant human H5 A/Anhui/1/2005 to various surfaces. 
500 ng of recombinant human H5 was immobilized to ELISA plates, carboxylic beads and Epoxy 
beads. 1/10 of the immobilization volume before and after immobilization was separated on a 10 % 
polyacrylamide gel and silver stained.  
Immobilization conditions for human H5 antigen that were applied for pannings are 
summarized in Fig 14. 
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6.1.2 Pannings using human naïve antibody libraries 
Naïve human scFv antibody phage-libraries HAL7 and HAL4 were constructed from 
non-immunized donors by Dr. Michael Hust and Saskia Helmsing188 and kindly 
provided for this work. Four different independent panning campaigns were 
performed using a pool of two different naïve human antibody libraries, HAL7 and 
HAL4. Two panning campaigns were performed on Epoxy beads using two different 
immobilization buffers. Third and fourth panning campaign were performed on 
carboxylic beads and ELISA plates, respectively. 
 
Figure 14: Panning strategy on human H5 A/Anhui/1/2005 with human naïve antibody libraries 
HAL7 and HAL4 
 
After two successive rounds of pannings for all bead based pannings and three 
panning rounds for plate based pannings no enrichment of phage numbers could be 
retainably observed (data not shown). Screening ELISA was performed for some 
clones derived from third round of panning but no signal-noise ratio of 2:1 or better 
was obtained. 
Since no H5 specific antibodies could be obtained from naïve human antibody 
libraries a competitve approach using H5 immunized chickens to construckt chicken 
immune libraries and select for H5 specific chicken antibodies was performed. 
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6.2 Generation of chicken immune libraries 
Total RNA from immunized chickens from peripheral blood lymphocytes and spleen 
was isolated by the group of Prof. Dr. Timm Harder at the FLI according to their 
procedures using RNeasy RNA isolation Kit (Qiagen).  
Nine samples (1-9) derived from blood samples (one double of one chicken for 
unknown reasons) and four samples (10-13) from spleen were used for library 
construction. 
6.2.1 Amplification of chicken antibody genes 
Generated cDNA was used for amplification of chicken antibody genes via PCR and 
a gel band of a size of about 400 bp was excised after separation on an agarose gel.  
VH and VL genes were amplified from all samples although DNA yield for samples 4 
and 6 for both antibody chains were very low (data not shown). DNA obtained from 
the first PCR amplification was used for a second PCR to introduce restriction sites to 
facilitate cloning into antibody phage display vectors. For all thirteen samples 
fragments with correct size of about 400 bp were amplified and excised from agarose 
gel (Fig 15). 
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Figure 15: Amplification from chicken antibody genes to introduce cleavage sites. 
Numbering of VH/VL is according to blood (1-9) or spleen (10-13) samples, respectively. Arrows 
indicate bands excised from gel corresponding with chicken antibody VL/VH. 
Differences in DNA amount observed after first PCR round were reduced after 
second PCR round and for all 13 samples sufficient DNA amounts were obtained to 
be cloned into phage display vector pHAL 14. 
6.2.2 Packaging of chicken antibody genes into phage libraries 
After restiction digest with appropriate restriction enzyme fragments were cloned into 
the pHAL 14 antibody phage display vector. Due to observed restriction for MluI of 
chicken VL and NcoI of chicken VH antibody genes (data not shown) the cloning 
strategy had to be modified to reduce negative effects on antibody library diversity.  
VH antibody gene fragments were cloned into pHAL14 first followed by introduction 
of VL antibody gene fragments into phage display vector pHAL 14 already containing 
VH fragments. 
After transformation pHAL 14 vectors containing VH and VL antibody fragments in E. 
coli XL1 blue a total amount of 5.7x106 cfu and 1.6x107 cfu independent clones were 
obtained derived from blood and spleen, respectively. 
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6.2.3 Colony PCR of clones from packaged chicken immune libraries 
Quality of constructed chicken anti-H5 immune libraries was analysed regarding 
numbers of independent clones obtained after transformation of pHAL14 phage 
display vector containing both antibody chains (VH and VL), percentage of 
incorporated full-size single-chain antibody gene fragments, phage titres of final 
chicken immune libraries after packaging of phagemid DNA into phages and fusion of 
single-chain antibodies on phage pIII-surface protein. 
Antibody fragments of 29 clones were amplified as a reperesentative for each 
chicken library. Concerning blood derived chicken library KFC2_AIV-B about 90 % of 
the analysed clones contained full-length antibody gene fragments of about 1100 bp. 
With regard to spleen derived library KFC2_AIV-S percentage of full-length inserts 
scored 100 % (Fig. 16) 
 
Figure 16: Colony PCR of clones from packaged chicken immune libraries 
ScFv-antibody fragments were amplified using pHAL14 vector specific oligonucleotides and separated 
on a 1% agarose gel. Correct full length scFv-antibody fragments show a band at ~ 900bp, clones 
missing one or both variable regions have bands of less than 900 bp and are indicated by *. 
6.2.4 Anti-pIII immunoblot 
After packaging of phagemid DNA into phages the following phage titres were 
obtained for both chicken anti-H5 immune libraries: for KFC2_AIV-B 1.3x1014 cfu/mL 
and for KFC2_AIV-S 9.4x1013 cfu/mL. Antibody phage preparations were analysed 
for the presentation of scFv-antibodies on the surface of the phage. A clear higher 
apparent fragment size of the pIII-protein of the phage preparations compared to 
wild-type pIII from helper phage was observed in the anti-pIII immunoblot (Fig 17). 
This difference in size indicates the fusion of the scFv antibody to the phage coat 
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protein pIII. 
 
Figure 17: Immunoblot of phage packaged chicken immune libraries 
Packaged phage preparations from blood (KFC2-AIV-B) and spleen (KFC2-AIV-S) derived chicken 
antibody phage libraries were separated under denaturing conditions on a polyacrylamide gel and 
blotted onto a PVDF-membrane. Detection was performed using an anti-pIII-antibody and a HRP-
labeled goat-anti-mouse-Fc specific antibody. Staining was performed using DAB substrate. M13KO7 
was used as reference of wildtype pIII (wt-pIII). Protein ladder was from Bio Rad. 
 
Generated chicken anti-H5 immune libraries were used for pannings on two different 
H5 antigens. 
6.3 Isolation of chicken anti-H5 antibodies 
To direct selection pressure towards the isolation of antibodies that broadly detect 
H5, two different recombinant H5 protein targets from different origins were 
introduced into the panning campaign: H5 from human origin (A/Anhui/1/2005) and 
H5 from avian origin (A/Canada goose/Germany/71/05). Pannings and screenings 
were performed separately on both targets. Only those antibodies that bound to both 
H5 antigens were further analysed. A summary of this procedure is given in (Fig 
12).Commercial recombinant human H5 A/Anhui/1/2005 protein was immobilized to 
magnetic beads using 10 mM sodium acetate buffer, pH 5.0. The biotinylated 
recombinant H5 A/Canada goose/Germany/71/06 provided by the group of Prof. 
Timm Harder at the FLI was produced as trimer 184 and captured using streptavidin 
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magnetic beads. 
6.3.1 Pannings using chicken immune libraries 
Panning campaigns applied for the identification of chicken H5-specific antibodies 
that broadly bind to H5 proteins from different origins are summarized in (Fig 12). 
Three successive rounds of pannings were performed on human recombinant H5 
antigen. Phage titre was stable from first to second round but showed from round two 
to three a more than 30 fold increase for KFC2_AIV-B and a nearly 100 fold fold 
increase for KFC2_AIV-S (Fig 38). Two successive rounds of pannings were 
performed on avian recombinant trimeric H5 antigen. Phage titre was stable from first 
to second round (Fig 39). 
To maintain the achieved diversity of bindersscreening ELISA were performed for 
clones derived from panning round two for both panning strategies. 
6.3.2 Screening for chicken scFv antibodies 
From the second round of panning 94 clones were screened for positive binders for 
each target and each library separately. Screening results are summarized in Tab 11.  
Table 11: Summary of screening ELISA on human H5 and avian H5 using scFv clones from 
chicken immune antibody libraries 
Examples of screening results are given in Figs 18 and 19. Twelve scFv antibodies 
with positive signals on both panning targets were subjected to further analyses.  
From 94 clones analysed on carboxy beads and to ELISA plates immoblized human 
H5 antigen more than 85% of all clones from each library showed positive signals on 
human H5 target. Signal was considered to be positive with a signal/noise ratio of 5:1 
or better at OD450 nm. In contrast, about 65% of all clones from pannings on avian H5 
antigen showed positive signals on the respective target captured via streptavidin 
magnetic beads from protein expression supernatant. The vast majority of human H5 
selected antibodies bound to plate immobilized-H5 as well as to bead immobilized-
H5. Some binders which showed positive signals on plate immobilized H5 but very 
low values on bead immobilized H5 were considered to be negative. Examples of 
screening data for both chicken antibody libraries KFC2_AIV-B and KFC2_AIV-S are 
  Results 
  74  
shown in Fig 18. and Fig 19 for the human and avian H5 target, respectively. 
 
Figure 18: Screening ELISA with chicken scFv clones obtained from pannings on recombinant 
human H5 A/Anhui/1/2005 (examples). 
ScFv-clones originating from pannings using chicken immune libraries constructed either from blood 
RNA (KFC2_AIV-B) or from spleen RNA (KFC2_AIV-S). Binding properties were analysed on 
recombinant H5 A/Anhui/1/2005 immobilized on carboxylic beads, on ELISA plates and on BSA. 
Overall signals on avian H5 antigen were relatively low compared to screening 
results on human H5 (Figs 18, 19) due to the assumed low amount of avian H5 
immobilized to streptavidin bead surface. As avian H5 protein from cell culture 
supernatant could only be detected in ECL stained immunoblot (Fig 21) H5 protein 
amount in the supernatant is assumed to be low. Furthermore, only a small amount 
of baculoviral expression supernatant was used for H5 immobilization to streptavidin 
beads with respect to the limited amount of avian H5 cell culture supernatant that 
was available for these analyses. All antibodies that bound avian H5 in screening 
ELISA also bound to human H5. 
  Results 
  75  
 
Figure 19: Screening ELISA with chicken scFv clones obtained from pannings on avian 
recombinant H5 A/Canada goose /Germany/71/06(examples). 
ScFv-clones originating from pannings using chicken immune libraries constructed either from blood 
RNA (A: KFC2_AIV-B) or from spleen RNA (B: KFC2_AIV-S) were analysed for binding on 
recombinant H5 A/Canada goose/Germany/71/06 immobilized to Streptavidin beads, and for negative 
control on empty Streptavidin (SA) beads, BSA and lysozyme – both immobilized on ELISA plates. A 
total of 10 µL baculoviral expression supernatant was immobilized to 1µL streptavidin beads and used 
per clone. 
6.4 Sequence analysis of isolated chicken antibodies 
All positive clones derived from screening ELISA were subjected to BstNI-digest to 
perform DNA fingerprinting (data not shown). A total of 30 individual clones were 
sequenced and revealed twelve different scFv antibodies (Fig 39). in the appendix). 
Up to five or eight amino acids have been inserted into CDR3 regions of VL or VH 
chains, respectively, compared to germline VH and VL sequences, in these twelve 
clones. Furthermore, genetic variability was observed in all CDRs. Six of the 
antibodies isolated (JM7_1, _2, _4, _10, _11, _13) share the same VH chain except 
for singe amino acid subtitutions in conserved regions but show major differences in 
their respective light chains. Antibodies JM03 and JM06 show major mutations in 
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CDR1 of VL chain. Both show the same insertion of five amino acids YAGSYY) in 
this region. Three hot spot regions of accumulated mutations occur between VL CDR 
2 and CDR 3, one at positions 220, 230 and 236.  
6.5 Cloning, production and purification of chicken scFv-Fc antibodies 
All twelve scFv antibodies JM7_01 to JM7-11 were cloned into expression vectors 
allowing the expression of scFc-Fc antibodies in mammalian cells with two scFv 
antibodies fused to an Fc-part of an antibody of either human or murine origin. 
All antibodies were cloned into pCMX2.5-hIgG1Fc and pCMV2.5-mIgG1Fc 
expression vectors (Figs 44, 45) allowing the expression of scFv-hIgG1Fc and scFv-
mIgG1Fc, respectively. Both variants of the scFv-Fc antibody format were expressed 
in adherent HEK293T cells.  
After the observation of instability of scFv-mIgG1Fc antibodies in SDS-PAGE 
analyses (data not shown) all twelve unique anti-H5 antibody clones were cloned into 
pCSE2.5-mIgG2cFc vector (Fig 43) allowing the expression of murine IgG2cFc and 
expressed in HEK293-6E cells cultures. 
6.6 Analyses of scFv-Fc antibodies 
6.6.1 Immunoblots 
For further investigation of antibody binding properties immunoblot with various H5 
samples, recombinant proteins and virus samples, and H7 for control was performed. 
For all immunoblots scFv-hIgG1Fc constructs were used. Influenza hemagglutinin 
shows a band at about 72 kD of apparent protein size on SDS-PAGE and in 
immunoblots  
All antibodies showed binding to recombinant panning target human H5 
A/Anhui/1/2005 (Fig 20) and except for antibody JM7_7 to recombinant panning 
target avian H5 A/Canada goose/Germany/71/05 as well (Fig 21).  
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Figure 20: Anti-human H5 A/Anhui/1/2005 immunoblot using scFv-hIgG1Fc antibodies. 
Recombinant target was separated on a 10 % SDS polyacrylamide gel and blotted onto PVDF 
membrane. Bound scFv-hIgG1Fc antibodies were detected using and HRP labeled anti-human-Fc-
antibody and TMB solution for staining. 
In Fig 21 clones JM7_3, JM7_9 and JM7_12 are idividual clones with identical amino-
acid sequence as well as clones JM7_13 and JM7_14. 
 
Figure 21: Anti-avian H5 A/Canada goose/Germany/71/06 immunoblot using scFv-hIgG1Fc 
antibodies. 
Baculovirus expression supernatant was separated o a 10 % SDS polyacrylamide gel and blotted onto 
a PVDF mebrane. Bound scFv-hIgG1Fc antibodies were detected via chemiluminescence using and 
HRP labeled anti-human-Fc-antibody and ECL-detection kit. 
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To further analyse whether antibodies bind to the head like structure HA1 of influenza 
hemagglutinin or to the stem like structure HA2, samples containing whole influenza 
viruses produced in embryonated chicken eggs were used for immunoblots (Fig 22, 
23). Upon protease cleavage during processing of influenza viruses in ECE 
unprocessed HA0 protein is cleaved into subunits HA1 (distal part of the 
hemagglutinin comprising knob like head of the protein and HA2 (membrane 
associated part of the hemagglutinin molecule). These three different hemagglutinin 
fractions HA0, HA1 and HA2 clearly differ in apparent molecular size in SDS-PAGE 
and immunoblot (HA0 ~ 72 kD, HA1 ~ 50 kD and HA2 ~ 26 kD) and antibody binding 
to either HA1 or HA2 subunit can be determined in immunoblots using processed 
influenza viruses. Three different H5 influenza virus strains were used for 
immunoblots (Figs 22, 23). and the H7 influenza virus in position 2 was chosen to 
control subtype specificity. 
Two sera from chickens immunized with H7 avian influenza virus (S87) and with H5 
avian influenza virus (S89) are used in immunoblot for reference (Fig 22). The anti-
H7 serum S87binds to HA0, HA1 and HA2 of influenza hemagglutinin and shows 
cross reactivity with H5 A/teal/Föhr/Wv632/05(lane 3) and H5 A/Vietnam/1197/2004 
(lane 4). S89 is known to be a ―monoclonal‖ anti-H5 serum and binds the HA2 
subunit of hemagglutinin 184. Nevertheless, it also shows binding to HA1 of 
H5A/teal/Föhr/Wv632/05 (lane 3), although HA1 shows unusual apparent size in this 
lane. 
 
Figure 22: Immunoblot of two different chicken anti-influenza hemagglutinin sera on different 
hemagglutinin targets 
Lane 1: H5 A/Canada goose/Germany/71/06, lane 2: H7 A/chicken/Germany/R28/03, lane3: H5 
A/teal/Föhr/Wv632/05, lane 4: H5 A/Vietnam/1197/2004; M: protein marker peqGold IV; HA0: 
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uncleaved precursor hemagglutinin, HA1: globular head domain of hemagglutinin, HA2: stalk domain 
of hemagglutinin; staining: chemiluminescence 
None of the antibodies bound to hemagglutinin H7 (lane 2) and theH5 
A/Vietnam/1197/2004 (lane 4) was difficult to detect or even undetectable. No 
antibody bound the HA2 fragment, thus all antibodies bind to HA1 subunit, the head 
like part of the hemagglutinin molecule. Antibodies JM7_15 and JM7_7 detected only 
unprocessed HA0 of H5 A/Canada goose/Germany/71/06 (lane1) but showed 
binding to cleaved HA1 of H5A/teal/Föhr/Wv632/05 (lane 3). Therefore, these two 
antibodies are considered to bind to HA1 part of influenza hemagglutinin as well. 
 
Figure 23: Immunoblot of different scFv-hIgG1Fc antibodies on different hemagglutinin targets. 
Virus samples were separated on a 10 % SDS polyacrylamide gel and blotted onto a PVDF mebrane. 
Lane 1: H5 A/Canada goose/Germany/71/06, lane 2: H7 A/chicken/Germany/R28/03, lane3: H5 
A/teal/Föhr/Wv632/05, lane 4: H5 A/Vietnam/1197/2004. Bound scFv-hIgG1Fc antibodies were 
detected via chemiluminescence using and HRP labeled anti-human-Fc-antibody and ECL-detection 
kit. M: protein marker peqGold IV; HA0: uncleaved precursor hemagglutinin, HA1: globular head 
domain of hemagglutinin, HA2: stalk domain of hemagglutinin, staining: chemiluminescence 
All selected antibodies bind to the head like structure of influenza hemagglutinin 
since exclusively unprocessed HA0 and HA1 hemagglutinin were bound in 
immunoblots. 
To further analyse thedetection of recently emerged highly variable escape mutants 
Egyptian H5N1 virus strain A/chicken/Egypt/0879-NLQP/2008-R737/09 was chosen 
for immunoblot. This virus has accumulated many mutations within the globular head 
of the hemagglutinin and thus effectively escapes from immune response 120,122,189.  
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Two o#f the isolated anti-H5 antibodies, JM7_6 and JM7_8, detected this Egyptian 
escape mutant in immunoblots (Fig 24). 
 
Figure 24: Immunoblot on inactivated virus A/chicken/Egypt/0879-NLQP/2008-R737/09 
using scFv-hIgG1Fc antibodies. 
Marker: protein marker peqGold IV, staining: chemiluminescence 
Antibody clones HJM7_6 and JM7_8 bound H5 to A/chicken/Egypt/0879-
NLQP/2008-R737/09.  
6.6.2 Detection of human and avian H5 antigen in ELISA using scFv-hIgG1Fc 
antibodies 
After expression and purification of scFv-hIgG1Fc antibodies these constructs were 
analysed on both panning targets again to demonstrate conservation of binding 
properties regarding these two targets (Fig 25). Values represent the means of 
absorbances of duplicate wells. 
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Figure 25: Binding of scFv-hIgG1Fc antibodies to recombinant human H5 and recombinant 
avian H5 A/Canada goose/Germany/71/06 
A total of 125 ng recombinant human H5A/Anhui/1/05 and lysozyme (for negative control) was 
immobilized per well to ELISA plates. Recombinant avian H5 A/Canada goose/Germany/71/06 was 
captured from baculoviral expression supernatant using streptavidin magnetic beads. A total of 500 ng 
scFv-hIgG1Fc antibodies was used per well with 200 µL supernatant per 1 µL beads and target bound 
antibodies was detected using HRP conjugated goat-anti-human-Fc antibody. 
6.6.3 Determination of antibody affinities and detection limits 
To determine minimal detectable amount of human recombinant H5 an antigen 
titration ELISA was perfomed and revealed that at least 5 ng per well were detectable 
with an absorption value of about 0.4 for all antibodies. (Fig. 40). Values represent 
mean absorbances of duplicate wells. 
A minimal amount of 1 - 5 ng scFv-hIgG1Fc antibody was necessary to obtain 
positive signals in antibody titration ELISA using 50 ng human H5 at an absorption 
value of 0.4-0.6 (Fig 41). Values represent mean absorbances of duplicate wells. 
Based on the molecular weight of scFv-Fc antibodies of ~ 104 kDa, the antibody 
binding curves obtained from antibody titration assay (Fig 41) with the indicated 
antibody concentrations the half maximal absorption values (EC50) of several scFv-
hIgG1Fc antibodies were calculated (Tab 12). All antibodies bound the human H5 
antigen in a subnanomolar range with the clone JM7_1 showing an EC50 of           
0.14 nmol/l. 
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Table 12: EC 50 values of scFv-hIgG1Fc antibodies 
 
6.6.4 Detection of H5 hemagglutinin in virus samples using capture ELISA 
In order to analyse epitope binding sites of the individual antibodies and to 
demonstrate their use in detection systems, capture ELISA and membrane based 
capture immunodot assays were performed.  
In capture ELISA both panning targets could be detected by different pairs of the 
selected antibodies (Figs 26 and 27). Signals for recombinant human H5 were higher 
compared to recombinant avian H5 since avian H5 of unknown concentration had to 
be captured from baculoviral expression supernatant whereas human H5 was used in 
a defined amount of 75 ng per well. For control and to analyse possible unspecific 
binding of immobilized scFv-h-IgG1Fc and detecting scFv-mouse IgG1Fc wells were 
incubated in 1% MPBST as blocking solution. Unspecific interaction of the two 
antibody formats was observed for JM7_1 but not for JM7_8 and JM7_3 (Fig 26). 
Values represent mean absorbances of duplicate wells. 
.
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Figure 26: Capture ELISA using recombinant human H5 A/Anhui/1/2005. 
500 ng of scFv-hIgG1Fc were immoblilized to ELISA plates per well. As a target 75 ng recombinant H5 A/Anhui/1/2005 was used. For detection 500 ng/well of 
scFv-mIgG2Fc and a HRP-labeled goat-anti-mouseFc antibody were used. As a negative control 1% MPBST was used instead of target (blocking). Staining was 
performed using TMB. 
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Figure 27: Capture ELISA using recombinant avian H5 A/Canada goose/Germany/71/06. 
400 ng of scFv-hIgG1Fc antibodies were immoblilized to ELISA plates per well. As a target 40 µL 
baculovirus expression supernatant of recombinant trimeric H5 A/Canada goose/Germany/71/06 was used 
and detected using 50µL JM7_1scFv, mouse-anti-myc-antibody and HRP-labeled goat-anti-mouseFc 
antibody. Staining was performed using TMB. 
Capturing of whole viruses from allantoic fluid preparations was also assayed (Fig 28). 
Viruses were propagated in embryonated chicken eggs. Initially all possible antibody 
combinations were analysed for capturing of H5N1 A/teal/FöhrWv632/05 virus preparation 
(data not shown). Antibody pairs successful in capturing A/teal/Föhr/Wv632/05 virus were 
applied in detailed capture ELISA using twelve different influenza virus preparations or 
antigens. The antibody combination JM7_1 scFv-hIgG1Fc and JM7_3 scFv-mIgG1Fc 
showed highest absorption signals and broadest virus detection spectrum restricted to H5 
viruses. Low pathogenic influenzua viruses A/mallard/B.C./544/05 (H5N9) and 
A/goose/Manitoba/428/06 (H5N2) remained undetectable (Fig 28). Concerning the 
inactivated virus preparations of highly pathogenic influenza viruses only A/Canada 
goose/Germany/71/06, the origin of the trimeric avian recombinant antigen used in 
panning campaigns, was detected. Under mild denaturing conditions (preincubation of 
virus preparation in 1 % Tween 20 or 1 MPBS over night incubation at 4 °C detection of 
A/mallard/B.C./544/05 could be improved (data not shown). In contrast under modified 
conditions a significant reduction in detection signal was observed for 
A/teal/Föhr/Wv632/05 (data not shown).  
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Figure 28: Capture ELISA using antibody pair JM7_1 scFv-hIgG1Fc/JM7_3 scFv-mIgG1Fc to detect different influenza viruses from allantoic fluid 
preparations 
A total amount of 500 ng of JM7_1 scFv-hIgG1Fc antibodies was immobilized to capture virus from allantoic fluid preparations. Virus antigen was adjusted to a 
minimal HA titre of 8 except for A/Mallard/Ger/Wv476/04 (H5N2) (HA-titre 5), A/mallard/B.C./544/05 (H5N9) (HA-titre 4) and A/chicken/Egypt/0918-NLQP/08 
H5N1 HP (R743) (HA-titre 6) due to low HA-titres of virus original preparation. A total amount of 500 ng JM7_3 scFv-mIgG1Fc antibody was used and HRP-
conjugated goat-anti-mouseFc antibody secondary antibody. To control quality of capturing antibodies 100 ng of recombinant human H5 A/Anhui/1/2005 was 
immobilized and binding of 500 ng of the respective scFv-Fc antibody was analysed. For scFv-hIgG1Fc antibody an HRP-conjugated goat-anti-hu 
manFc antibody was used as secondary antibody. For negative control blocking solution instead of virus was used (indicated by ‗block‘). Staining was performed 
using TMB. 
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6.6.5 Detection of H5 hemagglutinn in virus samples using a membrane based 
immunodot blot 
To show detection of whole viruses using a membrane based capturing system an 
immunodot blot was performed (Fig. 29) with an scFv-hIgG1-Fc antibody immobilized 
to a nitrocellulose membrane capturing the virus. ScFv-mIgG2-Fc antibody and an 
HRP labeled goat-anti-mouse Fc antibody were used for virus detection. Two 
different Fc-species were used to avoid crosss-reactivity of the labeled antibody with 
the immobilized capturing antibody. A 100 ng dot of scFv-hIgG1Fc antibody JM7_3 
was sufficient to capture avian influenza virus A/teal/Föhr/Wv632/05 from allantoic 
fluid produced in embryonated chicken eggs. 
 
Figure 29: Capture Immunodot blot using influenza virus A/teal/Föhr/Wv632/05. 
As an example 0.5mL supernatant of H5N1 avian influenza virus A/teal/Föhr/Wv632/05 produced in 
embryonated chicken eggs was used. Indicated amounts of JM7_03 scFv-hIgG1Fc antibody was 
immobilized and soluble JM7_1 mIgG2cFc antibody [2.5µg/mL] and alkaline phosphatase labeled 
goat-anti-mouse Fc- antibody was used for detection. Staining was performed using NBT/BCIP. 
6.6.6 Immunoperoxidase monolayer assay (IPMA) 
To further analyse H5 specificity of the isolated antibodies an ELISA on influenza 
virus infected cells was performed. A set of nine different low pathogenic avian 
influenza viruses of the H5 subtype and three non-H5 viruses (H1, H2, H6) were 
used to infect a swine testis cell line. Viral proteins are expressed in the cytoplasm 
and on the cell surface upon infection and can be detected by antibodies after 
fixation of the cells. To analyse antibody binding to highly pathogenic influenza 
viruses recombinant insect cells, which stably express viral H5 on their surface, were 
used. ScFv-hIgG1Fc antibodies were used throughout this assay. Tab 13 
summarizes the obtained results. 
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Table 13: Overview of IPMA results for all scFc-hIgG1Fc antibodies. 
   scFv-hIgG1Fc antibodies JM7_ 
Assay Hemagglutinin 
subtype 
Virus isolate 1 2 3 4 5 6 7 8 10 11 13 15 
IPMA H1 A/duck/Germersheim/R30/06 
(H1N1) 
- - - - - - - - - - - - 
ST-606 
cells 
infected 
with viruses 
H2 A/guinea fowl/Ger/DZ3/85 
(H2N2) 
- - - - - - - - + + - - 
H5 A/Vietnam/1194/2004 
(NiBrg14) (H5N1, HP) 
+ + + + + - + + + + - - 
A/teal/Föhr/Wv632/05 
(H5N1, LP) 
+ + + + + + + + + + + + 
A/goose/Manitoba/428/06 
(H5N2) 
+ + + + + + + + + + + + 
A/duck/Potsdam/1402/86 
(H5N2) 
+ + + + + - + + + + + - 
A/Mallard/Ger/Wv476/04 
(H5N2) 
+ + + + + + + + + + + + 
A/Mallard/Ger/Wv1349/03 
(H5N3) 
+ + + + + + + + + + + + 
A/duck/Potsdam/2216/84 
(H5N6) 
+ + + + + + + + + + + + 
A/chicken/Italy/22/98 
(H5N9) 
+ + + + + + + + + + + + 
A/mallard/B.C./544/05 
(H5N9) 
+ + + + + + + + + + + + 
H6 A/turkey/Germany/617/07 
(H6N2) 
+ - - - + - - - - - - - 
High-Five 
cells 
expressing 
recombinant 
target 
H5 A/chicken/Egypt/0879-
NLQP/2008 R737/09 
- - - - - + - + - - - - 
H5 A/Canada 
goose/Germany/71/06 
+ + + + + + - + + + + + 
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A total of eleven different hemagglutinins of the H5 subtypes were analysed and the 
vast majority of the antibodies bound well to these antigens. Only minor 
heterosubtypic binding to H2 (JM7_10 and JM7_11) and H6 (JM7_1 and JM7_5) was 
observed in this assay. As clones JM7_5 and JM7_3 are identical in amino acid 
sequence no clear result for this antibody clone can be stated with regard to its H6 
binding. None of the antibodies bound to H1. All antibodies detected a broad 
spectrum of H5 expressed on infected or recombinantly H5 expressing cells but only 
two antibody clones, JM7_8 and JM7_10 detected all eleven H5 viruses including the 
highly mutated Egyptian escape mutant strain (A/chicken/Egypt/0879-NLQP/2008 
R737/09).  
The antibody clone JM7_8 was the only antibody that bound to all eleven different H5 
without any cross-reactivity with other hemagglutinin subtypes. Binding of JM7_8 
antibody to recombinant insect cells expressing H5 variants of highly pathogenic 
avian influenza viruses is shown in Fig 30 and to a selection of H5 variants of low 
pathogenic avian influenza viruses in Fig 31. Compared to an chicken anti-
A/chicken/Egypt/0879-NLQP/2008-R737/09 serum antibody JM7_8 shows 
comparable binding to cells presenting H5 derived from A/chicken/Egypt/0879-
NLQP/2008-R737/09 on their surface.  
 
Figure 30: IPMA of clone JM7_8 scFv-hIgG1Fc on High Five insect cells expressing H5 of 
different highly pathogenic avian influenza strains. 
ScFv-hIgG1Fc antibodies on High Five insect cells recombinant expressingH5 of a) 
A/chicken/Egypt/0879-NLQP/2008-R737/09 (H5N1 HP) b) A/Canada goose/Germany/71/06 H5N1 HP 
c) A/Canada goose/Germany/71/06 (H5N1)detected by mAb 8292 (positive control), d) 
A/chicken/Egypt/0879-NLQP/2008-R737/09 (H5N1 HP) detected by anti R737 chicken serum 
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(positive control); secondary antibody for a) and b): anti-humanIgG Fc spezific HRP antibody; 
secondary anribody for c) and d): anti-chicken Fc specific HRP antibody 
 
An additional positive control for these stainings was a monoclonal antibody directed 
against the internal virus nucleoprotein NP (Fig 30c). Staining is comparable for 
antibody JM7_8 and anti-NP antibody on cells presenting the same H5 (Fig30b,c).) 
 
Figure 31: IPMA of clone JM7_8 scFv-hIgG1Fc on swine testis cells infected with different low 
pathogenic avian influenza strains. 
ScFv-hIgG1Fc antibodies on recombinant swine testis cells infected with a) A/teal/Föhr/Wv632/05 
(H5N1), b) A/chicken/Italy/22/98 (H5N9), c) A/duck/Potsdam/2216/84 (H5N6), d) 
A/goose/Manitoba/428/06 (H5N2), e) A/mallard/B.C./544/05 (H5N9), f)positive control 
A/turkey/Germany/617/07 (H6N2) anti-NP antibody, negative controls: g) A/turkey/Germany/617/07 
(H6N2),h) uninfected swine testis cells, i) A/chicken/Italy/22/98 (H5N9) anti-humanIgG Fc spezific 
HRP antibody 
Staining of H5 of infected swine testis cells is more directed to the surface of the cells 
(Fig 31a, b, c, e, and Fig 32a, b, c, d) compared to the anti-NP antibody used for 
positive control (Fig 31f) where staining is more prominent in the inner parts of the 
cell, which is consistent with the predominant localization of the respective target 
proteins. 
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Figure 32: IPMA of clone JM7_1 scFv-hIgG1Fc on swine testis cells infected with different low 
pathogenic avian influenza strains. 
ScFv-hIgG1Fc antibodies on recombinant swine testis cells infected with a) A/Mallard/Ger/Wv1349/03 
(H5N3) b) A/teal/Föhr/Wv632/05 (H5N1, LP) c) A/duck/Potsdam/1402/86 (H5N2) d) 
A/goose/Manitoba/428/06 (H5N2) e) A/duck/Germersheim/R30/06 (H1N1) f) uninfected swine testis cells 
with anti-humanIgG Fc spezific HRP antibody 
JM7_1-hIgG1Fc shows a broad H5 detection spectrum of all low pathogenic H5 variants 
but lacks detection of the highly mutated Egyptian escape mutant A/chicken/Egypt/0879-
NLQP/2008 R737/09and has minor cross-reactivity with H6. Binding of JM7_1-hIgG1Fc to 
a selection of H5 from low pathogenic influenza viruses is shown in Fig 32. Negative 
controls are shown in Fig 31 g-i with a non-H5 virus (H6N2) used for infection (Fig 31g), 
with the anti-humanFc-HRP conjugate alone on infected cells(Fig 31i). Uninfected swine 
testis cells stained with JM7_1-hIgG1Fc and anti-humanFc-HRP conjugate, remained 
completely unstained(Fig 31h). 
6.7 Electron microscopy TEM and SEM 
Influenza virus strain A/teal/Föhr/Wv63/05 was propagated in chicken eggs and specific 
binding of isolated scFv-hIgG1Fc antibodies was demonstrated for some antibodies in 
transmission electron microscopy (TEM). ScFv-Fc antibodies were labeled with 15 nm 
protein-A-gold particles. Specific binding of selected antibodies (black dots) JM7_3 and 
JM7_8 to A/teal/Föhr/Wv63/05 virus surface proteins was demonstrated for low (25 
ng/mL; Fig 33e, f) and higher (25 µg/mL; Fig 33g-k) antibody concentration. Resolution is 
higher for Fig 33a-c and Fig 33g-k than for Fig 33d-f.  
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Sample preparation and antibody labelling were performed in cooperation with Prof. Dr. 
Manfred Rohde (HZI), pictures were taken by Manfred Rohde and kindly provided. 
Specific binding of isolated chicken antibodies to whole influenza viruses is strongly 
indicated by these results. 
 
Figure 33: Transmission electron microscopy of influenza virus A/teal/Föhr/Wv632/05 and 
scFv-hIgG1Fc antibodies bound to the virus. 
A/teal/Föhr/Wv632/05 produced in embryonated chicken eggs after purification by ultracentrifugation (a-c), 
background binding of 15 nm protein-A-gold particles on virus preparation (d), – e) JM7_3 (25ng), f) JM7_8 
(25ng), g-k) JM7_3 (250µg) 
 
Figure 34: Scanning electron microscopy of JM7_3 scFv-hIgG1Fc antibodybound to influenza 
virusA/teal/Föhr/Wv632/05. 
A/teal/Föhr/Wv632/05 produced in embryonated chicken eggs after purification by ultracentrifugation 
detected with 15 nm protein-A-gold labeled JM7_3 scFv-hIgG1Fc antibody (a and b) 
TEM results were confirmed by scanning electron microscopy (SEM) showing gold-
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labeled antibodies (white dots) binding to the surface of influenza virions (Fig 34). Binding 
of several identical antibodies to the surface of a single virion was shown in TEM and 
SEM (Figs 33, 34).  
6.7.1 Hemagglutination Inhibition (HI) 
Since all identified antibodies bound to the head-like HA1 part of the hemagglutinin and 
this part is also target of most of the neutralizing antibodies hemagglutination inhibition 
tests were performed to analyse identified antibodies regarding their HI activity. The HI 
test probes the ability of the isolated antibodies to block agglutinating effects of viral 
hemagglutinin on erythrocytes. Typically, a positive HI test is a first hint on the virus 
neutralizing potential of an antibody.  
These tests were performed by Cornelia Illing in the group of Prof. Dr. Timm Harder. 
None of the identified H5 binders displayed HI activity against any of the H5-influenza 
viruses used in this assay ( Tab 14). 
Table 14: Hemagglutination Inhibition Assay (HI) for anti-H5 scFv-hIgG1Fc antibodies. 
HI was performed using freshly prepared chicken blood and a serial dilution of indicated virus strains and of 
H5 specific scFv-hIgG1Fc antibodies. No hemagglutination inhibition is indicated by a ‗-‗,  
 
6.7.2 Virus Neutralization Assay (VN) 
To further analyse neutralization activity of identified chicken antibodies 
microneutralization assays were performed in a 96 well scale using MDCK+ cells. Viral 
infectious dosis was 100 TCID50. Measurements were performed in quadruplets. 
According to the standard procedure applied at the FLI (first adding trypsin to the seeded 
cells and second preincubated antibody-virus-mixture) only antibody JM7-3 showed broad 
neutralizing activity for eight different H5-influenza strains. Except for 
A/mallard/B.C/5445/05 (H5N9) all H5 viruses assayed were neutralized by this antibody. 
Neutralizing activity was restrained to viruses of H5 subtype. Viruses of H1, H2 and H6 
subtypes were not neutralized. 
The standard procedure was altered and trypsin was added after a six hours incubation of 
preincubated antibody-virus-mixture and seeded cells. Under these conditions additionally 
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JM7_8 could be identified as a neutralizing antibody (Tab. 15). Neutralization was 
assayed for JM7_8 only using virus A/teal/Föhr/Wv632/05 and A/mallard/B.C./544/05. 
Antibody titration was performed for both antibodies JM7_8 and JM7_3 to a minimum of 
0.13 nM which was the end point of titration. Both antibodies showed still complete 
neutralization at this low antibody concentration. 
Additional analyses revealed a complete digest of scFv-mIgG2cFc antibodies JM7-8, 
JM7_1 and JM7_10 and an only partial but significant degradation of JM7_3 after a 1 h 
incubation with trypsin at 37 °C (data not shown). 
Table 15: Virus microneutralization assay for isolated anti-H5 scFv-mIgG2cFc antibodies. 
The assay was performed using MDCK
+
 cells and indicated viruses were used at 100 TCID50, ‗+‘complete 
neutralization of all four wells, ‗-‗ no neutralization, empty fields: assay not performed. 100 TCID50 was 
confirmed by titration for each virus in the same assay. 
 
6.8 Epitope mapping for two H5 specific antibodies 
For antibodies JM7_8 and JM7_1 epitope mapping was successfully performedusing 
peptide spot membrane. Membrane was designed on the basis of the H5 sequence of 
A/Anhui/1/2005. Consistent with the results from immunoblot using virus preparations (Fig 
24) both epitopes are located in the HA1 part of the hemagglutinin molecule. 
The epitope of JM7_8 revealed to be a six amino acid strech with the amino acid 
sequence FPNVVW at hemagglutinin positions 146-152 (PDB accession number 2FK0). 
The epitope appears to be rather hidden in the crystal structure (Fig 35.) Location of the 
epitope in top and side view of the crystal structure is shown as well as detection spots on 
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the peptide spot membrane and derived amino acid sequence of the respective epitope. 
 
 
Figure 35: Three dimensional picture of the HA trimers of avian hemagglutinin and epitope of 
antibody clone JM7_8. 
A) and B) represent thwo different views (A – side view; B – top view) of HA trimers; HA1 molecules are 
highlighted (orange, green, blue); epitope of JM7_8 antibody is shown in red. Epitope membrane is shown 
in C) and amino acid sequence of peptides detected by the antibody is shown in D). Assumed antibody 
peptide is shown in red. (molecular structure reference: 2IBX pdb VN1194 Yamanada) 
 
For antibody clone clone JM7_1 two different sites of antibody binding were detected on 
the peptide spot membrane Fig 36. One epitope including peptides 74 – 76 with the amino 
acid sequence VPKIATRSK the other epitope comprises peptide numbers 111 – 115 with 
the amino acid sequence ERRRKR, which includes the cleavage site of the 
hemagglutinin. But as shown in IPMA and immunoblot assays JM7_1 binds equally well to 
H5 from highly and low pathogenic influenza viruses which show major differences in their 
cleavage sites. This antibody cannot provide specific binding of the influenza cleavage 
site region. 
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Figure 36: Three dimensional picture of the HA trimers of avian hemagglutinin and epitope of 
antibody JM7_1. 
a) and b) represent thwo different views (A – side view; B – top view) of HA trimers; HA1 molecules are 
highlighted (orange, green, blue); epitope of JM7_1 antibody is shown in magenta. epitope membrane is 
shown in c) and Amino acid sequence of peptides detected by the antibody is shown in d for peptides 111-
115 and in e) for peptides 74-76. Assumed antibody peptide is shown in magenta. molecular structure 
reference: 2IBX pdb VN1194 
190
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7 Discussion 
Highly pathogenic H5N1 avian influenza virus (HPAIV H5N1) devastates the poultry 
industry worldwide causing enormous economic losses. In addition, the virus poses a 
significant pandemic threat to human health. Due to the vital role of hemagglutinin 
protein (HA) in viral infections and in escape from treatment and control, different 
strategies targeting the HA have been developed for diagnosis, vaccine design and 
therapeutic applications. Recombinant neutralizing antibodies (rnAbs) specific to the 
HA protein were used for diagnostic purposes and protection studies. A rapid 
subtype specific detection system compatible with field application for highly 
pathogenic avian influenza viruses will be useful in surveillance of the rapidly 
changing viruses but depends on highly conserved epitopes allowing the 
discrimination of certain virus subtypes, especially H5 and H7, the only highly 
pathogenic avian influenza virus suptypes observed to date in the field. 
This work aimed at the isolation and characterization of broadly reactive antibodies 
specific for influenza viruses of the H5 subtype. 
From the universal human naïve antibody phage libraries HAL7 and HAL 8 177 no H5 
specific antibodies were isolated, although about 300 antibody clones were analysed 
after three different panning campaigns. Obviously, the isolation of anti-H5 antibodies 
from human naïve libraries poses a challenge. Published data on human naïve 
antibody libraries for the selection of anti-H5 antibodies are rare. The human 
antibody libraries of Throsby et al. and Sun et al. were generated from vaccinated or 
naturally infected donors, respectively, and therefore are no naïve human 
libraries191,192. Lim and coworkers 193 have used the commercial human Fab library 
from Humanyx (Singapore) of undeclaredimmune status of donors §. Of similar 
undisclosed immune origin has been a human scFv antibody library of Yang et al194. 
Although a successful isolation of neutralizing anti-H5 antibodies from all these 
human antibody libraries has been shown, these libraries may not be comparable to 
human naïve antibody phage libraries like HAL7 and HAL 4.  
 
Libraries generated from H5 infected or vaccinated humans 191,192 evidently have a 
                                                 
 
§Lim et al.declared the use of a naïvehuman Fab antibody library HX01 from Humanyx (Singapore). 
This library specification cannot be deduced from information provided on the homepage of the 
company. 
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non-naïve antibody gene repertoire. Likewise, one may assume a similar post 
contact status with regard to H5 for undisclosed donors from which antibody libraries 
in Asian institutes were constructed193,194. In Asia the increased contact to H5N1 
viruses due to frequent H5N1 outbreaks in poultry and living of humans in close 
proximity to poultry clearly differ from the situation in Europe. While antibody genes 
of European donors predominate the antibody libraries HAL7 and HAL4, a 
comparable bias towards antibody genes of Asian origin may be supposed for the 
libraries of Yang et al. and Lim et al. These aspects may have facilitated the isolation 
of anti-H5 antibodies from these libraries. Immune antibody libraries are a well 
accepted tool to increase the probability of success in antibody isolation to a given 
antigen195. 
7.1 High quality anti-H5 immune antibody phage libraries were obtained from 
chickens 
As birds are the natural host for H5 influenza viruses and are susceptible, chickens 
were chosen to be immunized and boosted with different H5 influenza viruses. In 
addition, due to conserved regions flanking chicken antibody genes chicken antibody 
libraries are easily to be constructed. Only two sets of oligonucleotides were 
sufficient to amplify chicken antibody gene fragments from RNA185. Two independent 
libraries were constructed from peripheral blood lymphocytes and from splenic RNA 
to access the complete diversitiy of the antibody repertoire of the immunized donors 
as reported before 185,196–200. Random pairing of VH and VL gene fragments was 
allowed thus creating an artificial antibody diversity without assured conservation of 
the original donor VH-VL combinations. Unexpectedly, degradation of antibody gene 
fragments occurred due to restriction sites within the chicken antibody genes. 
Deleterious restriction sites were cleaved by the enzymes NcoI and MluI immanent to 
the employed phage display vector. This drawback has not been described in 
literature, as others use different restriction enzymes like ApaLI/NotI196, SfiI/NotI200, 
Sapats SalI/NotI and AscI/XbaI198, NotI201 and SfiI197,202 for chicken antibody library 
construction. Hence, a reduction of antibody gene diversity for the chicken libraries 
generated in this work must be taken into consideration. Nevertheless, the quality of 
the anti-H5 chicken immune libraries was underlined by a total number of up to 107 
independent clones after transformation of antibody gene containing phagemid 
vectors, up to 100 % correct fragment size and a clear presentation of scFv 
antibodies on the surface of the phage along with a high phage titre of both antibody 
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phage libraries. Although the human naïve antibody libraries HAL7 and HAL4 show a 
larger complexicity (109 individual clones) than the constructed chicken anti-H5 
immune libraries, implementation of immune libraries was more successful in this 
project. Numerous anti-H5 antibodies have already been isolated from human 
antibody libraries 191,192,203,204. Yet, as most of them either exhibited cross-reactivity 
with other hemagglutinin subtypes or did not broadly detect H5, it is likely that they 
would not have fullfilled the aim of the project.  
To direct antibody binding characteristics towards the desired broad H5-binding 
activity four different H5 antigens were introduced into the selection. Two 
phylogenetic distant avian influenza viruses influenced the chicken in vivo selection 
after immunization and two different highly pathogenic recombinant H5 antigens were 
used in the in vitro selection process. The latter two different H5 antigens, originating 
from viruses of human and avian origin, have been implemented in two separate 
panning campaigns. Two rounds of pannings were sufficient for both targets to 
isolate a total of twelve different antibody clones binding both H5 variants specifically. 
This is in contrast to the selection strategies based on a single H5 antigen 
191,192,194,202. Similar to the selection strategy using heterologous H5 antigens 
presented in this work, Lim et al. have used two different recombinant H5 antigens193. 
Of note, the majority of their isolated antibodies bound to linear epitopes. In contrast 
to this, the dominance of conformational epitopes of selected antibodies using 
different virus-like particles is demonstrated in the same work. Wang et al. have 
shown that broadly protective antibodys against H3 were elicited after sequential 
immunization with four different viruses205. Therefore, the applied extented 
heterologous selection strategy herein may have contributed to both – the isolation of 
antibodies with broad H5 specificity on one hand and the isolation of antibodies 
exclusively binding linear epitopes on the other hand. 
7.2 Isolated antibodies specifically bind to linear epitopes and detect H5 
influenza viruses wihout or with low cross-reactivity towards different HA 
subtypes 
The two different H5 antigens applied in selection and screening were derived from 
human (A/Anhui/1/2005) or avian (A/Canadagoose/Germany/71/06) influenza 
viruses, respectively. The human antigen was monomeric whereas the avian H5 was 
a trimer that was captured from baculoviral production supernantant using 
streptavidin beads. Although only bead immobilized human H5 was used in the 
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selection process the vast majority of selected antibodies bound to plate immobilized 
human H5 as well as to bead immobilized human H5. Hence it can be either 
concluded that presentation of H5 on beads and plate did not differ very much in the 
performed assays under the  applied conditions or that, if presentation differs, bound 
epitopes are accessible in both ways of presentation. The importance of 
immobilization strategies for the isolation of antibodies binding certain conformational 
epitopes has been described earlier, demonstrating that bead immobilized 
recombinant antigens may provide a more naturally shaped antigen surface206 . A 
total of twelve antibodies bound to both recombinant H5 antigens in ELISA. All twelve 
antibodies detected human recombinant H5 antigen and the majority of them also 
avian recombinant H5 antigen as well as two further H5 viruses propagated in 
chicken eggs in immunoblots under denaturing conditions. From these results it can 
be concluded that all selected antibodies bind to linear epitopes since conformational 
epitopes tend to be destroyed under these conditions. In addition all epitopes are 
located in the head like part of the hemagglutinin, since exclusively HA0 and HA1 
were detected in immunoblots. Unexpectedly, two antibodies (JM7_6 and JM7_8) 
detected the hemagglutinin of a highly pathogenic H5 escape mutant 
(A/chicken/Egypt/0879-NLQP/2008-R737/09), that has amassed numerous 
mutations in its hemagglutinin120. Thus, at least for these two antibodies broad H5 
detection and highly conserved epitopes can be assumed.Highly conserved subtype 
specific epitopes in the highly variable head-like part of the hemagglutinin are rare. In 
contrast to this, strain specific neutralization of influenza viruses is based to a large 
extent on antibodies binding near receptor binding sites207,208. The well accessible 
HA1 part plays a major role in antigenic drift and frequent mutations in this part of the 
protein assist the virus in escaping from immune responses8,50. Nevertheless, few 
highly conserved epitopes had been mapped to the HA1 part207,209. In contrast, 
broadly neutralizing hemagglutinin specific antibodies are more likely to bind to the 
more conserved stalk-like structure of the hemagglutinin210–213.  
Furthermore, specificity of isolated antibodies was demonstrated using nine different 
low pathogenic avian H5 influenza viruses and three H5 antigens of highly 
pathogenic viruses by specific staining of infected or recombinant H5 expressing 
cells (IPMA), respectively. Eight individual antibodies detected all low pathogenic H5 
antigens. The highly pathogenic avian H5 antigen, already used in selections was 
detected by all of them in this assay. Minor cross-reactivity was observed for a total 
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of four antibodies with subtypes H2 or H6. None of the clones bound to H1 in the 
virus infection assay or H7 in immunoblot. Low background staining observed in this 
assay underlines the specificity of the isolated antibodies. Specific antibody binding 
to the surface of influenza viruses was clearly shown in electron microscopic pictures 
obtained with purified H5 influenza virus preparations and immunogold labeled 
antibodies. Once more, low antibody background binding was demonstrated based 
on both, a good virus preparation with low amount of free hemagglutinin and virus 
debris and highly specific anti-H5 antibodies. 
Furthermore, as a proof of principle for an antibody based detection system capture 
ELISA with scFv-Fc antibodies differing at least in their Fc-part were carried out. 
Eight out of twelve different H5 influenza viruses or respective antigens could be 
detected. No cross-reactivity with H1 and H2 viruses has been observed which was 
consistent with results obtained from cell infection assay. Under mild denaturing 
conditions an improved detection of the virus A/mallard/B.C/544/05 H5N9 could be 
obtained whereas other viruses remained undetectable under these conditions. 
Moreover, for A/teal/Föhr/Wv632/05 these conditions turned out do be unfavourable 
since detection of this virus was abolished then. One may speculate that partial 
unfolding of the hemagglutinin could have caused these effects. Accessibility of 
antibody epitopes may be different and dependent on structural integrity of the 
hemagglutinin at least to a certain extent. To obtain a complete virus detection 
spectrum detection should be performed under both conditions, mild denaturing and 
non-denaturing. Surprisingly, not all antibody combinations were capable of detecting 
viruses from propagated chicken egg samples. Influenza viruses present several 
hundred hemagglutinin molecule entities on their surface. Hence, all antibody 
combinations should work as capture and detection antibodies in ELISA. As this 
could not be demonstrated for all antibodies, one may conclude that free soluble 
hemagglutinin possessing each antibody binding site only once per molecule is 
detected from the virus samplesrather than complete viruses. Only in the case that 
the detecting antibody epitope is still accessible while the capturing antibody has 
already bound to the soluble antigen, capture ELISA will work. Few antigen capture 
ELISA (AC-ELISA) using chicken egg derived virus preparations have been 
described. He et al. demonstrated the use of two different antibody formats (IgG and 
IgM) binding different epitopes for capturing and pooled hyperimmune sera for 
detection of H5 viruses214. The applied antibody amount was comparable to the work 
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presented here with 100 ng capture and 800 ng detection antibody. In this AC-ELISA 
four H5 viruses were discriminated from five viruses of different HA subtypes and the 
detection limit was detemined to be 124 TCID50. A similar AC-ELISA was developed 
for the detection of H7 viruses with a detection limit of 102-103 TCID50
86. In the case 
that soluble hemagglutinin interferes with capturing of viruses the determination of a 
detection limit with a TCID50 or a hemagglutination titre may not aid. Since both 
values estimated whole virus particles which in turn appear not to be detected in the 
AC-ELISA described in this work, recombinant human H5 antigen was used in AC-
ELISA. Detection limit for this antigen was below 75 ng per well. Under the 
assumption that the same epitope theoretically exists only once per molecule 
antibody pairs sharing the same scFv fragment should not be capable of detecting 
soluble recombinant H5 antigen. Unexpectedly, those homologous antibody pairs 
were effective in detection of the used recombinant antigen. Hence, a spontaneous 
multimerization of the soluble recombinant antigen must be assumedSpontaneous 
multimerization of soluble recombinant hemagglutinin has been observed (J. Skehel, 
personal comm.). The estimated detection limit cannot be compared with published 
data. The described challenge of interfering soluble hemagglutinin is circumvented by 
an AC-ELISA using an anti-H5 antibody for capturing and an anti-N1 antibody for 
detection215. As both antibodies detect highly conserved epitopes, nevertheless, this 
assay is restricted to H5N1 viruses and exclusively detects virus particles or 
membrane fragments harbouring both HA and NA molecules. In contrast, the major 
advantage of a detection system based on soluble hemagglutinin and linear epitopes 
is its increased robustness in field application. Reduction of viral integrity and partial 
unfolding of viral hemagglutinin in natural samples may frequently occur. 
A membrane based detection format was assayed as an additional proof of principle. 
A total of 100 ng membrane bound antibody was sufficient to give a positive 
signalafter detection with a respective antibody possessing a different Fc-part. Hong 
et al. have demonstrated a detection system combining the nitrocellulose membrane 
immobilized capture antibody with a magnetic bead immobilized detection 
antibody216. This biosensor allows the detection of viral protein in the picogram range 
via magnetic sensors.  
Beyond antibody specificity and detection limit, antibody affinity is a further important 
parameter for the design of detection systems. EC50 values of all analysed antibodies 
reached subnanomolar ranges. Due to restriction in antigen availability and instability 
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of the chicken scFv antibodies EC50 values were calculated from titration ELISA with 
scFv-hIgG1Fc antibodies and represent apparent affinities. Published antibody 
affinities based on biosensor studies and H1 hemagglutinin range from 1.7 x 10-7 – 
4.8 x 10-11 M 207,217 and values within this range (5 x 10-10 M and 1.7 x 10-10 M) were 
obtained for neutralizing antibodies binding the receptor-binding site of H3218. These 
biosensor based values cannot be directly compared to obtained EC50 values from 
titration ELISA. However, the best EC50 value of 1.4 x 10
-10 M for antibody clone 
JM7_1 indicate very good affinities of the isolated anti-H5 antibodies. High affinities 
are indispensible in detection systems when minor or even trace amounts of virus or 
antigens thereof shall be detected. 
7.3 Two antibodies specifically neutralize H5 influenza viruses 
Virus neutralization and thus protective potential of antibodies with broadest H5 
binding spectrum was analysed in HI and virus neutralization tests. Two of the four 
tested antibodies showed virus neutralization restricted to H5 viruses. No 50 % 
endpoint tiration titres were determined since both antibodies JM7_8 and JM7_3 still 
showed complete neutralization at 1.3 x 10-10 M and 100 TCID50. Antibody 
neutralization titre must therefore be below this value. Throsby et al. have published 
IC50 values of 3 x 10-9 for neutralizing antibodies with regard to H5 viruses and    
1.96 x 10–7 for heterosubtypic viruses192. Antibody clone JM7_3 neutralization was 
successful with standard procedure for eight of the analysed nine viruses. Only 
A/mallard/B.C./544/09 H5N9 virus was not neutralized. Control viruses of the 
hemagglutinin subtypes H1, H2 and H6 were not neutralized. For clone JM7_8 no 
neutralization was observed with standard procedure. Following the assumption that 
trypsin facilitating the infection of MDCK cells in the case of low pathogenic influenza 
viruses may degrade antibodies and thus prevent neutralization, virus neutralization 
procedure was altered. Susceptibility of IgG to proteolytic digest with trypsin has 
been described earlier by Brown et al.219. Surprisingly, no published comment on the 
observed antibody degradation during virus neutralisation assay could be found. 
After a six hours delay in trypsin addition antibody JM7_8 conferred neutralization at 
least for A/teal/Föhr/Wv632/05 to the same low antibody neutralization titre as JM7_3 
at the endpoint of titration. Complete degradation of applied antibodies due to the 
proteolytic activity of trypsin was shown in separate assays with antibody clone 
JM7_3 showing partial resistance to tryptic digest. This could explain why standard 
neutralization procedure was successful for this antibody.  
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From the neutralizing effect of the antibodies and the elucidated HA1 specificity of 
both of them can be concluded that the epitopes of JM7_8 and JM7_3 interfere with 
the receptor binding site of the hemagglutinin. However, all antibodies were negative 
in HI test. This result is contradictory to the virus neutralization test results since both 
assays analyse the inhibition of the receptor binding activity of viral hemagglutinin. 
This failure in HI may be either due to the structure and potentially reduced flexibility 
of the artificial chimeric antibodies (chicken scFv and human Fc) or due to 
undisclosed factors contributing to a less effective interplay of chicken erythrocytes 
with human serum in HI reported earlier 220. Moreover, goose erythrocytes were 
reported to be beneficial in hemagglutination assay with H5N1 viruses221. The failure 
of HI assay could therefore be false negative results caused by assay immanent 
factors. The observation that human H3 influenza viruses have lost the ability to 
agglutinate chicken erythrocytes is of further interest222. This indicates that the 
hemagglutination and hemagglutination inhibition assay applied to influenza viruses 
may need additional revision with regard to reliability. 
7.4 Antibody sequences 
The deduced amino acid sequence of the isolated twelve individual antibody clones 
revealed insertions of up to eight amino acids in VH CDR3 and frequent mutations in 
framework and CDR regions of VL indicating that gene conversion and insertion of 
pseudogenes had taken place 167,169. The CDR3 regions of both antibody chains 
showed the highest variability as was expected since the antigen binding region is 
built up to a large extent by these parts of the antibody. Amino acid substitutions 
within the constant framework regions flanking the variable CDRs provide an 
indication of somatic hypermutation involved in antibody gene diversification 223. 
Framework mutations may affect binding affinities to a surprisingly large extent 224. 
Five antibodies shared basically the same VH chain but clearly differed in VL 
segments. This so-called VH promiscuity has been observed in human antibody 
fragments as well 225 and supports the notion that antibody heavy chains tend to 
have stronger contribution to antigen binding than light chains 226.  
7.5 Antibody clone JM7_8 revealed a highly conserved H5 specific 
neutralizing epitope 
Attempts to map the epitopes of two of the isolated antibodies concentrated on using 
a peptide spot membrane derived from the amino acid sequence of human H5 
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A/Anhui/1/2005. Mapping for the antibody clone JM7_8 revealed the six amino acid 
short epitope FRNVVW at amino acid positions 143-149 (H5 numbering 227 / H3 
positions 147-153 H3 numbering 228). This conserved linear structure is flanked by 
much more variable regions i) the antigenic region A 228 (RCSB file pdb 2hmg) also 
named 140 S loop (H5 positions 136-141), to which binding of neutralizing antibodies 
was already shown 229 and ii) the glycosylation site at position 158-160 35. Modelling 
revealed that the FRNVVW epitope is rather hidden in the structure of the 
hemagglutinin and deletion of the adjacent glycosylation site, as recently reported for 
emerging Asian H5 influenza viruses230,231 could improve accessibility of the epitope 
and thus facilitate detection. The recently described N158D mutation confering 
improved replication to a droplet transmissible avian influenza virus in the ferret 
model55 is close to but not within the defined conserved epitope. Since this mutation 
abolishes a glycosylation site its contribution to an improved accessiblity of the 
conserved epitope at position 148-153 can be assumed. Nevertheless, an influence 
of mutations at this glycosylation site on the shape and accessibility of the linear 
epitope remains to be investigated. Computational analyses have previously 
indicated that the defined epitope FRNVVW could be an antigenic peptide 227. The 
tryptophane at the end of the epitope is involved in receptor binding, thus an antibody 
to this epitope can possibly have have neutralizing activity. Furthermore, from cross-
protection vaccination studies a fifteen amino acid long epitope KSSFRNVVWLIKKN 
comprising the shorter six amino acid epitope was published and shown to be 
conserved among H5 influenza viruses and assumed to be involved in protection 
against heterologous H5 challenge232. Since the antibody JM7_8 directed against the 
short epitope FRNVVW was shown to bind a linear epitope, detected H5 from various 
influenza strains and demonstrated neutralization of at least H5 virus 
A/teal/Föhr/Wv632/05 cross-protection potential of this peptide sequence can be 
assumed. Sequence alignments of 2466 European,Asian, African, North American 
and Egyptian H5 virus isolates revealed a 95.7% conservation of the six amino acid 
epitope (Tab 16) (personal communication Abdelwhab, FLI, unpublished data). Thus, 
this epitope is highly conserved within H5 influenza viruses. Furthermore it is not 
present in H1 viruses. 
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Table 16: Comparison of hemagglutinin epitope conservation among H5 influenza virus 
isolates 
 
 
Failure in neutralization of A/mallard/B.C./544/09 using the antibody JM7_8 may be 
due to glycosylation at position 158-160 which is typical of most American and old 
Asian H5 viruses35 and may sterically hinder antibody binding. The same effect may 
have had led to negative results in AC-ELISA for this virus. This assumption is 
supported by the observation that this virus became detectable in AC-ELISA under 
mild denaturing conditions. Sterical hinderance may have been moderated under 
these conditions. 
Up to now, no linear epitopes in the highly variable globular structure of influenza 
hemagglutinin Egyptian escape mutant A/chicken/Egypt/0879-NLQP/2008-R737/09 
shared with other H5 influenza hemagglutinins were known.Thus, a highly conserved 
very short epitope applicable for vaccination studies and diagnostic purposes along 
with the respective neutralizing antibody has been elucidated.  
Two different binding sites were revealed for antibody clone JM1_7. Epitope 
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ERRRKR of peptides 111-115 include the highly pathogenic cleavage site of the H5 
hemagglutinin. The cleavage site of low pathogenic H5 influenza viruses consists of 
only one arginine. Since antibody clone JM7_1 has been shown to bind comparably 
well to H5 from highly and low pathogenic influenza viruses in IPMA and immunoblot 
assays, it is rather unlikely that this antibody provides specific binding of the influenza 
cleavage site region. The false positive signals on peptide spot membrane may be 
due unspecific binding to the positively charged arginines and lysines.The epitope 
VPKIATRSK (210–218 H5 numbering227) is a more likely correct epitope of antibody 
clone JM7_1 and has previously been predicted to be an antigenic peptide by 
computational methods227. This epitope is not as well conserved as the epitope of 
JM7_8 as JM7_1 did not detect the Egyptian escape mutant H5. Obviously this 
epitope is not restricted to H5 influenza viruses since the antibody clone JM7_1 
showed cross-reactivity with H6. 
Published data on further highly conserved epitopes in the head-like part of the H5 
protein are rare. Chen et al have identified a neutralizing antibody binding a 
conformational epitope including positions 158 and 182209,233 whereas Velumani and 
coworkers have described the antigenic linear epitope CNTQCNTP at positions 274-
281 (H5 numbering227)234. 
7.6 Possible applications in diagnostics, therapy and vaccination of isolated 
anti-H5-antibodies and the identified epitope 
The antibodies isolated in this work can be used for diagnostic purposes in systems 
such as lateral flow devices (LFD), ELISA based applications and biosensors. 
Application of isolated antibodies in lateral flow devices can be proposed as highly 
specific broad H5 detecting antibodies have been isolated. As antibody clone JM7_8 
was capable of detecting a large variety of H5 influenza viruses without showing 
cross-reactivity to heterosubtypic viruses this antibody has an outstanding potential 
for this application. Additionally, the determined subnanomolar affinities provide an 
excellent basis for the development of such a detection system, although it remains 
to be evaluated whether the achievable detection limits meet the requirements. Two 
commercially available LFDs (Anigen Rapid AIV Ag Test Kit, BioNote Inc., Korea; 
QuickVue Influenza test, QUIDEL, USA) are based on the detection of the viral 
nucleoprotein and are therefore not subtype specific. Both LFDs were tested in field 
situations in Egypt and revealed a detection limit of at least 104 virus particles82,235 
which is a 1000 fold lower sensitivity compared to PCR based detection. As up to 
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now only H5 and H7 influenza viruses have shown to be able to naturally convert 
from low pathogenic to highly pathogenic influenza viruses the proposed H5 subtype 
specific detection system would be of fundamental advantage for surveillance and 
disease control. Likewise, the isolated antibodies can be applied in biosensors. For 
H7 and H8 influenza virus detection the successful use of an inferometric biosensor 
has been reported236. As mentioned in section 6.2, Hong et al. have developed a 
magnetic biosensor capable of detecting the antigen in picomolar amounts, 
applicable for point-of-care diagnostics and in a 96-well format216. To support the use 
of biosensors in the field a miniaturised biosensor has been introduced237.  
ELISA based detection systems using two antibody entities binding the antigen may 
be difficult due to the need of complementary antibody pairs recognizing different 
epitopes and capable of detecting soluble hemagglutinin. With antibody clones 
JM7_1 and JM7-3 such an antibody pair could be proposed, yet not all analysed H5 
viruses were detectable. Furthermore, broad range H5 detecting antibody JM7_8 
could be used as capture antibody in ELISA based applications along with pooled 
hyperimmune sera for detection. The detection limit of 1 HAU in an AC-ELISA using 
anti-H5 and anti-N1 antibodies recognizing highly conserved epitopes has been 
reported 238. A dot ELISA using complementary antibodies detecting highly 
conserved epitopes of H5 avian influenza viruses has been described239. 
Besides their usefulness in diagnostics, isolated antibodies may be used for 
therapeutic purposes with regard to passive immunization. In the case of a pandemic 
outbreak of influenza viruses neutralizing antibodies could be used for passive 
immunization and treatment.As long as no universal influenza antibody is available, 
subtype specific antibodies may be helpful. After the humanization of the isolated 
neutralizing antibody clones JM7_8 and JM7_3 by maintaining affinity, specificity and 
neutralizing activity the antibodies could be used in humans. A successfull 
humanization of chicken scFv antibodies has been demonstrated240. All isolated scFv 
antibodies were of chicken origin. An application of a complete scFv chicken antibody 
extented by a chicken Fc-part in passive poultry immunization could be possible. Yet 
economic cost benefit calculations clearly prevent this application. Given that the 
necessary antibody stability could be provided passive immunization of chickens via 
the oral route with egg yolk IgY is achievable. The successful oral immunization of 
chickens against Vibrio cholerae applying this method has been shown241.  
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Most valuable result of this work with regard to vaccination is the elucidated highly 
specific linear epitope of antibody clone JM7_8. As this antibody shows neutralizing 
activity the respective linear epitope used as a vaccine potentially confers immune 
protection to H5 influenza viruses. The epitope is linear and short and therefore less 
prone to formation of a secondary structure that could destroy the epitope and hinder 
successful vaccination. Nevertheless, antigenicity of the epitope as well as 
vaccination conditions including adjuvants remain to be investigated. Wang et al. 
have shown a successful immunization in mice using a synthetic peptide mapping to 
the stalk-like part of the hemagglutinin. After immunization mice were protected 
against lethal challenge with influenza viruses of the subtypes H5, H3 and H1242.  
Additionally to these potential application of the already isolated antibodies it is 
noteworthy that constructed chicken antibody phage libraries most likely contain 
antibodies recognizing viral neuraminidase N1 which could easily be isolated and 
analysed for their characteristics, potentials and applications. 
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Figure 37: Phage titres after pannings on human H5 immobilized on carboxy-beads using 
chicken immune anti-H5 libraries (PR1-3: the three successive rounds of pannings). 
 
 
Figure 38: Phage titres a after pannings on avian H5 immobilized on Streptavidin beads using 
chicken immune anti-H5 libraries 
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Figure 39: Amino acid sequence alignment of isolated anti-H5 chicken antibodies. 
 Amino acid identity to the germ-line sequences are shown in grey (cyan), differences in black, absence of corresponding residue by dashes. CDR and Yol-linker 
of scFv annotated. As germline reference sequences AAA48861.1 (NCBI database) was used for VL and the VH sequence is according to Yamanaka (1996) 
with an X indicating hypervariable positions. 
  Appendix 
  X  
 
Figure 40: Titration ELISA of human H5 A/Anhui/1/2005 using scFv-hIgG1Fc antibodies. 
H5 was immobilized to ELISA plates in a range between 5 – 75 ng/well and detected using 500ng 
scFv-hIgG1Fc antibodies per well and HRP-labeled goat-anti-human-Fc-antibody (Sigma A0170). 
 
Figure 41: Titration of scFv-hIgG1Fc antibodies on human H5 A/Anhui/1/2005. 
50 ng of recombinant H5 A/Anhui/1/2005 was immobilized to ELISA plates.  
Antibody binding was analysed in a range of 400-0.25 ng/ well and target bound antibodies  
were detected using HRP-labeled goat-anti-human-Fc-antibody (Sigma A0170). 
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Epitope membrane peptides using 
hemagglutinin of H5N1 
A/Anhui/1/2005 
 
1   MEKIVLLLAIVSLVK 
2   IVLLLAIVSLVKSDQ 
3   LLAIVSLVKSDQICI 
4   IVSLVKSDQICIGYH 
5   LVKSDQICIGYHANN 
6   SDQICIGYHANNSTE 
7   ICIGYHANNSTEQVD 
8   GYHANNSTEQVDTIM 
9   ANNSTEQVDTIMEKN 
10  STEQVDTIMEKNVTV 
11  QVDTIMEKNVTVTHA 
12  TIMEKNVTVTHAQDI 
13  EKNVTVTHAQDILEK 
14  VTVTHAQDILEKTHN 
15  THAQDILEKTHNGKL 
16  QDILEKTHNGKLCDL 
17  LEKTHNGKLCDLDGV 
18  THNGKLCDLDGVKPL 
19  GKLCDLDGVKPLILR 
20  CDLDGVKPLILRDCS 
21  DGVKPLILRDCSVAG 
22  KPLILRDCSVAGWLL 
23  ILRDCSVAGWLLGNP 
24  DCSVAGWLLGNPMCD 
25  VAGWLLGNPMCDEFI 
26  WLLGNPMCDEFINVP 
27  GNPMCDEFINVPEWS 
28  MCDEFINVPEWSYIV 
29  EFINVPEWSYIVEKA 
30  NVPEWSYIVEKANPA 
31  EWSYIVEKANPANDL 
32  YIVEKANPANDLCYP 
33  EKANPANDLCYPGNF 
34  NPANDLCYPGNFNDY 
35  NDLCYPGNFNDYEEL 
36  CYPGNFNDYEELKHL 
37  GNFNDYEELKHLLSR 
38  NDYEELKHLLSRINH 
39  EELKHLLSRINHFEK 
40  KHLLSRINHFEKIQI 
41  LSRINHFEKIQIIPK 
42  INHFEKIQIIPKSSW 
43  FEKIQIIPKSSWSDH 
44  IQIIPKSSWSDHEAS 
45  IPKSSWSDHEASSGV 
46  SSWSDHEASSGVSSA 
47  SDHEASSGVSSACPY 
48  EASSGVSSACPYQGT 
49  SGVSSACPYQGTPSF 
50  SSACPYQGTPSFFRN 
51  CPYQGTPSFFRNVVW 
52  QGTPSFFRNVVWLIK 
53  PSFFRNVVWLIKKNN 
54  FRNVVWLIKKNNTYP 
55  VVWLIKKNNTYPTIK 
56  LIKKNNTYPTIKRSY 
57  KNNTYPTIKRSYNNT 
58  TYPTIKRSYNNTNQE 
59  TIKRSYNNTNQEDLL 
60  RSYNNTNQEDLLILW 
61  NNTNQEDLLILWGIH 
62  NQEDLLILWGIHHSN 
63  DLLILWGIHHSNDAA 
64  ILWGIHHSNDAAEQT 
65  GIHHSNDAAEQTKLY 
66  HSNDAAEQTKLYQNP 
67  DAAEQTKLYQNPTTY 
68  EQTKLYQNPTTYISV 
69  KLYQNPTTYISVGTS 
70  QNPTTYISVGTSTLN 
71  TTYISVGTSTLNQRL 
72  ISVGTSTLNQRLVPK 
73  GTSTLNQRLVPKIAT 
74  TLNQRLVPKIATRSK 
75  QRLVPKIATRSKVNG 
76  VPKIATRSKVNGQSG 
77  IATRSKVNGQSGRMD 
78  RSKVNGQSGRMDFFW 
79  VNGQSGRMDFFWTIL 
80  QSGRMDFFWTILKPN 
81  RMDFFWTILKPNDAI 
82  FFWTILKPNDAINFE 
83  TILKPNDAINFESNG 
84  KPNDAINFESNGNFI 
85  DAINFESNGNFIAPE 
86  NFESNGNFIAPEYAY 
87  SNGNFIAPEYAYKIV 
88  NFIAPEYAYKIVKKG 
89  APEYAYKIVKKGDSA 
90  YAYKIVKKGDSAIVK 
91  KIVKKGDSAIVKSEV 
92  KKGDSAIVKSEVEYG 
93  DSAIVKSEVEYGNCN 
94  IVKSEVEYGNCNTKC 
95  SEVEYGNCNTKCQTP 
96  EYGNCNTKCQTPIGA 
97  NCNTKCQTPIGAINS 
98  TKCQTPIGAINSSMP 
99  QTPIGAINSSMPFHN 
100 IGAINSSMPFHNIHP 
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101 INSSMPFHNIHPLTI 
102 SMPFHNIHPLTIGEC 
103 FHNIHPLTIGECPKY 
104 IHPLTIGECPKYVKS 
105 LTIGECPKYVKSNKL 
106 GECPKYVKSNKLVLA 
107 PKYVKSNKLVLATGL 
108 VKSNKLVLATGLRNS 
109 NKLVLATGLRNSPLR 
110 VLATGLRNSPLRERR 
111 TGLRNSPLRERRRKR 
112 RNSPLRERRRKRGLF 
113 PLRERRRKRGLFGAI 
114 ERRRKRGLFGAIAGF 
115 RKRGLFGAIAGFIEG 
116 GLFGAIAGFIEGGWQ 
117 GAIAGFIEGGWQGMV 
118 AGFIEGGWQGMVDGW 
119 IEGGWQGMVDGWYGY 
120 GWQGMVDGWYGYHHS 
121 GMVDGWYGYHHSNEQ 
122 DGWYGYHHSNEQGSG 
123 YGYHHSNEQGSGYAA 
124 HHSNEQGSGYAADKE 
125 NEQGSGYAADKESTQ 
126 GSGYAADKESTQKAI 
127 YAADKESTQKAIDGV 
128 DKESTQKAIDGVTNK 
129 STQKAIDGVTNKVNS 
130 KAIDGVTNKVNSIID 
131 DGVTNKVNSIIDKMN 
132 TNKVNSIIDKMNTQF 
133 VNSIIDKMNTQFEAV 
134 IIDKMNTQFEAVGRE 
135 KMNTQFEAVGREFNN 
136 TQFEAVGREFNNLER 
137 EAVGREFNNLERRIE 
138 GREFNNLERRIENLN 
139 FNNLERRIENLNKKM 
140 LERRIENLNKKMEDG 
141 RIENLNKKMEDGFLD 
142 NLNKKMEDGFLDVWT 
143 KKMEDGFLDVWTYNA 
144 EDGFLDVWTYNAELL 
145 FLDVWTYNAELLVLM 
146 VWTYNAELLVLMENE 
147 YNAELLVLMENERTL 
148 ELLVLMENERTLDFH 
149 VLMENERTLDFHDSN 
150 ENERTLDFHDSNVKN 
151 RTLDFHDSNVKNLYD 
152 DFHDSNVKNLYDKVR 
153 DSNVKNLYDKVRLQL 
154 VKNLYDKVRLQLRDN 
155 LYDKVRLQLRDNAKE 
156 KVRLQLRDNAKELGN 
157 LQLRDNAKELGNGCF 
158 RDNAKELGNGCFEFY 
159 AKELGNGCFEFYHKC 
160 LGNGCFEFYHKCDNE 
161 GCFEFYHKCDNECME 
162 EFYHKCDNECMESVR 
163 HKCDNECMESVRNGT 
164 DNECMESVRNGTYDY 
165 CMESVRNGTYDYPQY 
166 SVRNGTYDYPQYSEE 
167 NGTYDYPQYSEEARL 
168 YDYPQYSEEARLKRE 
169 PQYSEEARLKREEIS 
170 SEEARLKREEISGVK 
171 ARLKREEISGVKLES 
172 KREEISGVKLESIGT 
173 EISGVKLESIGTYQI 
174 GVKLESIGTYQILSI 
175 LESIGTYQILSIYST 
176 IGTYQILSIYSTVAS 
177 YQILSIYSTVASSLA 
178 LSIYSTVASSLALAI 
179 YSTVASSLALAIMVA 
180 VASSLALAIMVAGLS 
181 SLALAIMVAGLSLWM 
182 LAIMVAGLSLWMCSN 
183 MVAGLSLWMCSNGSL 
184 GLSLWMCSNGSLQCR 
185 LWMCSNGSLQCRICI 
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Figure 42: Plasmid map for pCSE2.5-mIgG2cFc-XP-TS262.21 vector allowing the expression of 
scFv-mIgG2cFc antibodies in eukaryotic cells. 
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Figure 43: Plasmid map for pCMX2.5-hIgG1Fc-XP vector allowing the expression of scFv-
hIgG1Fc antibodies in eukaryotic cells. 
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Figure 44: Plasmid map for pCMV-mIgG1Fc-XP vector allowing the expression of scFv-
mIgG1Fc antibodies in eukaryotic cells. 
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